All Stories

  1. Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis

    Article • Clinical Research in Cardiology, September 2021, Springer Science + Business Media

    Professor John GF Cleland

  2. The genomics of heart failure: design and rationale of the HERMES consortium

    Article • ESC Heart Failure, September 2021, Wiley

    Professor John GF Cleland, Marie-Pierre Dubé

  3. A Global Perspective of Racial Differences and Outcomes in Patients Presenting with Acute Heart Failure

    Article • American Heart Journal, September 2021, Elsevier

    Professor John GF Cleland

  4. To master heart failure, first master congestion

    Article • The Lancet, September 2021, Elsevier

    Professor John GF Cleland, Dr Pierpaolo Pellicori

  5. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

    Article • European Heart Journal, August 2021, Oxford University Press (OUP)

    Professor John GF Cleland

  6. A qualitative exploration of participant and investigator perspectives from the TRED‐HF trial

    Article • ESC Heart Failure, August 2021, Wiley

    Professor John GF Cleland

  7. Under-recognition of heart failure in patients with atrial fibrillation and the impact of gender: a UK population-based cohort study

    Article • BMC Medicine, August 2021, Springer Science + Business Media

    Professor John GF Cleland

  8. Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial

    Article • Cardiovascular Diabetology, August 2021, Springer Science + Business Media

    Professor John GF Cleland, Dr Pierpaolo Pellicori

  9. Right Ventricular Ejection Fraction and Beta-Blocker Effect in Heart Failure With Reduced Ejection Fraction

    Article • Journal of Cardiac Failure, August 2021, Elsevier

    Professor John GF Cleland

  10. A novel treatment for heart failure targets myocardial fibrosis

    Article • Nature Medicine, August 2021, Springer Science + Business Media

    Professor John GF Cleland, Dr Pierpaolo Pellicori

  11. Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF

    Article • European Journal of Heart Failure, August 2021, Wiley

    Professor John GF Cleland

  12. Ethnic differences in prevalence of actionable HbA1c levels in UK Biobank: implications for screening

    Article • BMJ Open Diabetes Research & Care, August 2021, BMJ

    Professor John GF Cleland, Dr Pierpaolo Pellicori

  13. Use of Social Media by Cardiovascular Health Care Professionals

    Article • JACC Cardiovascular Imaging, August 2021, Elsevier

    Professor John GF Cleland, Dr Pierpaolo Pellicori

  14. Reply to the letter regarding the article ‘Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure’

    Article • European Journal of Heart Failure, July 2021, Wiley

    Professor John GF Cleland, Dr Pierpaolo Pellicori

  15. Stem cell therapy for dilated cardiomyopathy

    Article • Cochrane Database of Systematic Reviews, July 2021, Wiley

    Professor John GF Cleland, Professor Rienzi A Diaz Navarro

  16. Remote history of VTE is associated with severe COVID‐19 in middle and older age: UK Biobank cohort study

    Article • Journal of Thrombosis and Haemostasis, July 2021, Wiley

    Professor John GF Cleland, Dr Pierpaolo Pellicori

  17. Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF

    Article • Cardiovascular Research, July 2021, Oxford University Press (OUP)

    Professor John GF Cleland

  18. A comparison of non‐invasive methods of measuring body composition in patients with heart failure: a report from SICA‐HF

    Article • ESC Heart Failure, July 2021, Wiley

    Professor John GF Cleland, Dr Pierpaolo Pellicori

  19. The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure

    Article • Journal of Cardiac Failure, July 2021, Elsevier

    Professor John GF Cleland

  20. Heart Rate as a Marker of Relapse During Withdrawal of Therapy in Recovered Dilated Cardiomyopathy

    Article • JACC Heart Failure, July 2021, Elsevier

    Professor John GF Cleland

  21. Identification of sex‐specific biomarkers predicting new‐onset heart failure

    Article • ESC Heart Failure, June 2021, Wiley

    Professor John GF Cleland

  22. New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial

    Article • Clinical Research in Cardiology, June 2021, Springer Science + Business Media

    Professor John GF Cleland

  23. Association between up‐titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum

    Article • European Journal of Heart Failure, June 2021, Wiley

    Professor John GF Cleland

  24. Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure

    Article • The American Journal of Cardiology, June 2021, Elsevier

    Professor John GF Cleland

  25. Substantial decline in hospital admissions for heart failure accompanied by increased community mortality during COVID-19 pandemic

    Article • European Heart Journal - Quality of Care and Clinical Outcomes, May 2021, Oxford University Press (OUP)

    Professor John GF Cleland

  26. Use of diuretics and outcomes in patients with type 2 diabetes: Findings from the EMPA‐REG OUTCOME trial

    Article • European Journal of Heart Failure, May 2021, Wiley

    Professor John GF Cleland, Dr Pierpaolo Pellicori

  27. Extra‐cardiac targets in the management of cardiometabolic disease: Device‐based therapies

    Article • ESC Heart Failure, May 2021, Wiley

    Professor John GF Cleland

  28. Non‐adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography‐tandem mass spectrometry (results of a prospective multicentre study)

    Article • European Journal of Heart Failure, May 2021, Wiley

    Professor John GF Cleland, Dr Dan Lane

  29. Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute Heart Failure

    Article • JACC Heart Failure, May 2021, Elsevier

    Professor John GF Cleland

  30. Correspondence to European Heart Journal—Quality of Care and Clinical Outcomes in response to paper by Thomas, M. et al. 2021: Predicting the EQ-5D from the Kansas City Cardiomyopathy Questionnaire (KCCQ) in patients with heart failures

    Article • European Heart Journal - Quality of Care and Clinical Outcomes, April 2021, Oxford University Press (OUP)

    Professor John GF Cleland

  31. Impaired High‐Density Lipoprotein Function in Patients With Heart Failure

    Article • Journal of the American Heart Association, April 2021, Wolters Kluwer Health

    Professor John GF Cleland

  32. The struggle towards a Universal Definition of Heart Failure—how to proceed?

    Article • European Heart Journal, April 2021, Oxford University Press (OUP)

    Professor John GF Cleland, Dr Pierpaolo Pellicori

  33. Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF

    Article • JACC Heart Failure, April 2021, Elsevier

    Professor John GF Cleland, Dr Pierpaolo Pellicori

  34. Telomere length is independently associated with all-cause mortality in chronic heart failure

    Article • Heart, March 2021, BMJ

    Professor John GF Cleland

  35. Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials

    Article • Clinical Research in Cardiology, March 2021, Springer Science + Business Media

    Professor John GF Cleland, Dr Pierpaolo Pellicori

  36. Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction

    Article • European Journal of Heart Failure, March 2021, Wiley

    Professor John GF Cleland

  37. Prognostic value of the chest X-ray in patients hospitalised for heart failure

    Article • Clinical Research in Cardiology, March 2021, Springer Science + Business Media

    Professor John GF Cleland, Dr Pierpaolo Pellicori

  38. The value of spot urinary creatinine as a marker of muscle wasting in patients with new‐onset or worsening heart failure

    Article • Journal of Cachexia Sarcopenia and Muscle, March 2021, Wiley

    Professor John GF Cleland, Dr Pierpaolo Pellicori

  39. The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and ...

    Article • European Heart Journal, March 2021, Oxford University Press (OUP)

    Professor John GF Cleland

  40. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies

    Article • Cochrane Database of Systematic Reviews, March 2021, Wiley

    Professor John GF Cleland, Dr Pierpaolo Pellicori

  41. Haemodynamic effects of the nitroxyl donor cimlanod ( BMS ‐986231) in chronic heart failure: a randomized trial

    Article • European Journal of Heart Failure, March 2021, Wiley

    Professor John GF Cleland

  42. Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHESUS, and EXAMINE

    Article • Clinical Research in Cardiology, March 2021, Springer Science + Business Media

    Professor John GF Cleland

  43. Serum potassium and outcomes in heart failure with preserved ejection fraction: a post‐hoc analysis of the PARAGON‐HF trial

    Article • European Journal of Heart Failure, March 2021, Wiley

    Professor John GF Cleland

  44. Impact of Geographic Region on the COMMANDER-HF Trial

    Article • JACC Heart Failure, March 2021, Elsevier

    Professor John GF Cleland

  45. Temporal trends in heart failure medication prescription in a population-based cohort study

    Article • BMJ Open, March 2021, BMJ

    Professor John GF Cleland

  46. Pregnancy intention data completeness, quality and utility in population-based surveys: EN-INDEPTH study

    Article • Population Health Metrics, February 2021, Springer Science + Business Media

    Professor John GF Cleland

  47. Effects of a Novel Nitroxyl Donor in Acute Heart Failure

    Article • JACC Heart Failure, February 2021, Elsevier

    Professor John GF Cleland, Prof HECTOR BUENO

  48. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

    Article • New England Journal of Medicine, January 2021, New England Journal of Medicine (NEJM/MMS)

    Professor John GF Cleland

  49. The association between blood groups and COVID‐19 infection: a study from the UK Biobank

    Article • Journal of Internal Medicine, January 2021, Wiley

    Professor John GF Cleland, Dr Pierpaolo Pellicori

  50. Is acute heart failure a distinctive disorder? An analysis from BIOSTAT‐CHF

    Article • European Journal of Heart Failure, January 2021, Wiley

    Professor John GF Cleland

  51. Relation Between Thyroid Function and Mortality in Patients With Chronic Heart Failure

    Article • The American Journal of Cardiology, January 2021, Elsevier

    Professor John GF Cleland

  52. Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy: insights from TRED‐HF

    Article • European Journal of Heart Failure, December 2020, Wiley

    Professor John GF Cleland

  53. Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants

    Article • Occupational and Environmental Medicine, December 2020, BMJ

    Professor John GF Cleland

  54. High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality

    Article • European Journal of Heart Failure, December 2020, Wiley

    Professor John GF Cleland

  55. Protocol for an implementation study of an evidence-based home cardiac rehabilitation programme for people with heart failure and their caregivers in Scotland (SCOT:REACH-HF)

    Article • BMJ Open, December 2020, BMJ

    Professor John GF Cleland

  56. Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure

    Article • Circulation Heart Failure, December 2020, Wolters Kluwer Health

    Professor John GF Cleland

  57. Ultrasound imaging of congestion in heart failure: examinations beyond the heart

    Article • European Journal of Heart Failure, November 2020, Wiley

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  58. A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure

    Article • European Journal of Heart Failure, November 2020, Wiley

    Professor John GF Cleland

  59. Correction to: The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure

    Article • Clinical Research in Cardiology, November 2020, Springer Science + Business Media

    Professor John GF Cleland

  60. Conduct of Clinical Trials in the Era of COVID-19

    Article • Journal of the American College of Cardiology, November 2020, Elsevier

    Professor John GF Cleland

  61. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials

    Article • European Journal of Heart Failure, October 2020, Wiley

    Professor John GF Cleland

  62. Plasma D ‐dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER‐HF trial

    Article • European Journal of Heart Failure, October 2020, Wiley

    Professor John GF Cleland

  63. Differences in biomarkers and molecular pathways according to age for patients with HFrEF

    Article • Cardiovascular Research, October 2020, Oxford University Press (OUP)

    Professor John GF Cleland

  64. Serum uric acid, influence of sacubitril–valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON‐HF

    Article • European Journal of Heart Failure, September 2020, Wiley

    Professor John GF Cleland

  65. Muscle wasting as an independent predictor of survival in patients with chronic heart failure

    Article • Journal of Cachexia Sarcopenia and Muscle, August 2020, Wiley

    Professor John GF Cleland

  66. Correction to: Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study

    Article • The Lancet Global Health, August 2020, Elsevier

    Professor John GF Cleland

  67. Implications of serial measurements of natriuretic peptides in heart failure: insights from BIOSTAT‐CHF

    Article • European Journal of Heart Failure, July 2020, Wiley

    Professor John GF Cleland

  68. Structural heart disease, cardiac dysfunction and heart failure: the ambiguity of a definition

    Article • European Journal of Preventive Cardiology, July 2020, SAGE Publications

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  69. Author Correction: Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease

    Article • Nature Medicine, July 2020, Springer Science + Business Media

    Professor John GF Cleland

  70. Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial

    Article • European Journal of Heart Failure, July 2020, Wiley

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  71. Artificial Intelligence Needs Clinical Intelligence to Succeed

    Article • JACC Heart Failure, July 2020, Elsevier

    Professor John GF Cleland

  72. The year in cardiology 2019: heart failure

    Article • Romanian Journal of Cardiology, June 2020, Societatea Romana de Cardiologie

    Professor John GF Cleland

  73. Effects of combined renin–angiotensin–aldosterone system inhibitor and beta‐blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT‐CHF and ASIAN‐HF registries

    Article • European Journal of Heart Failure, June 2020, Wiley

    Professor John GF Cleland

  74. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

    Article • European Heart Journal, June 2020, Oxford University Press (OUP)

    Professor John GF Cleland

  75. Caring for people with heart failure and many other medical problems through and beyond the COVID ‐19 pandemic: the advantages of universal access to home telemonitoring

    Article • European Journal of Heart Failure, June 2020, Wiley

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  76. The year in cardiology: heart failure
The year in cardiology 2019

    Article • Cardiologia Croatica, June 2020, Medical Publishing, d.o.o.

    Professor John GF Cleland

  77. Myocardial injury in severe COVID-19 infection

    Article • European Heart Journal, May 2020, Oxford University Press (OUP)

    Professor John GF Cleland

  78. Relationship between a single measurement at baseline of body mass index, glycated hemoglobin, and the risk of mortality and cardiovascular morbidity in type 2 diabetes mellitus

    Article • Cardiovascular Endocrinology & Metabolism, May 2020, Wolters Kluwer Health

    Professor John GF Cleland

  79. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors

    Article • European Heart Journal, May 2020, Oxford University Press (OUP)

    Professor John GF Cleland

  80. Tumour biomarkers: association with heart failure outcomes

    Article • Journal of Internal Medicine, May 2020, Wiley

    Professor John GF Cleland

  81. Future research prioritization in cardiac resynchronization therapy

    Article • American Heart Journal, May 2020, Elsevier

    Professor John GF Cleland

  82. Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial

    Article • JACC Heart Failure, May 2020, Elsevier

    Professor John GF Cleland

  83. Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials

    Article • Heart Failure Reviews, April 2020, Springer Science + Business Media

    Professor John GF Cleland

  84. Eplerenone prevents an increase in serum carboxy‐terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure

    Article • European Journal of Heart Failure, April 2020, Wiley

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  85. A network analysis to identify pathophysiological pathways distinguishing ischaemic from non‐ischaemic heart failure

    Article • European Journal of Heart Failure, April 2020, Wiley

    Professor John GF Cleland

  86. Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure

    Article • JAMA Cardiology, April 2020, American Medical Association (AMA)

    Professor John GF Cleland

  87. Heart failure treatment up‐titration and outcome and age: an analysis of BIOSTAT‐CHF

    Article • European Journal of Heart Failure, March 2020, Wiley

    Professor John GF Cleland

  88. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study

    Article • The Lancet Global Health, March 2020, Elsevier

    Professor John GF Cleland

  89. Predictors of left ventricular remodelling in patients with dilated cardiomyopathy – a cardiovascular magnetic resonance study

    Article • European Journal of Heart Failure, February 2020, Wiley

    Professor John GF Cleland

  90. Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction

    Article • Clinical Research in Cardiology, January 2020, Springer Science + Business Media

    Professor John GF Cleland

  91. Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study

    Article • Clinical Research in Cardiology, January 2020, Springer Science + Business Media

    Professor John GF Cleland

  92. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof‐of‐concept, randomised, precision‐medicine, prevention trial. The Heart OMics in AGing ...

    Article • European Journal of Heart Failure, January 2020, Wiley

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  93. The year in cardiology: heart failure

    Article • European Heart Journal, January 2020, Oxford University Press (OUP)

    Professor John GF Cleland

  94. OUP accepted manuscript

    Article • European Heart Journal, January 2020, Oxford University Press (OUP)

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  95. Chronic Obstructive Pulmonary Disease and Heart Failure

    Article • Heart Failure Clinics, January 2020, Elsevier

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  96. Temporal trends in the incidence, treatment patterns, and outcomes of coronary artery disease and peripheral artery disease in the UK, 2006–2015

    Article • European Heart Journal, December 2019, Oxford University Press (OUP)

    Professor John GF Cleland

  97. What do patients with heart failure die from? A single assassin or a conspiracy?

    Article • European Journal of Heart Failure, December 2019, Wiley

    Professor John GF Cleland

  98. Glycated Hemoglobin, Prediabetes, and the Links to Cardiovascular Disease: Data From UK Biobank

    Article • Diabetes Care, December 2019, American Diabetes Association

    Professor John GF Cleland

  99. Selenium and outcome in heart failure

    Article • European Journal of Heart Failure, December 2019, Wiley

    Professor John GF Cleland

  100. Clinical value of pre‐discharge bio‐adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission

    Article • European Journal of Heart Failure, December 2019, Wiley

    Professor John GF Cleland

  101. Cardiovascular and non‐cardiovascular death distinction: the utility of troponin beyond N‐terminal pro‐B‐type natriuretic peptide. Findings from the BIOSTAT‐CHF study

    Article • European Journal of Heart Failure, December 2019, Wiley

    Dr Joao Pedro Ferreira, Professor John GF Cleland

  102. Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure

    Article • Journal of the American College of Cardiology, December 2019, Elsevier

    Professor John GF Cleland

  103. Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets

    Article • European Journal of Heart Failure, November 2019, Wiley

    Professor John GF Cleland

  104. Association of Fitness and Grip Strength With Heart Failure

    Article • Mayo Clinic Proceedings, November 2019, Elsevier

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  105. Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF

    Article • European Journal of Internal Medicine, November 2019, Elsevier

    Dr Joao Pedro Ferreira, Professor John GF Cleland

  106. Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease

    Article • Nature Medicine, November 2019, Springer Science + Business Media

    Professor John GF Cleland

  107. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality

    Article • JACC Heart Failure, November 2019, Elsevier

    Professor John GF Cleland

  108. Temporal Trends and Patterns in Mortality After Incident Heart Failure

    Article • JAMA Cardiology, November 2019, American Medical Association (AMA)

    Professor John GF Cleland

  109. Trajectories of Changes in Renal Function in Patients with Acute Heart Failure

    Article • Journal of Cardiac Failure, November 2019, Elsevier

    Professor John GF Cleland

  110. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

    Article • New England Journal of Medicine, October 2019, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy, Professor John GF Cleland

  111. Electrocardiographic characteristics in patients with heart failure and normal ejection fraction: A systematic review and meta‐analysis

    Article • Annals of Noninvasive Electrocardiology, October 2019, Wiley

    Professor John GF Cleland

  112. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study

    Article • The Lancet, October 2019, Elsevier

    Professor John GF Cleland

  113. Stem cell.

    Article • Cochrane Database of Systematic Reviews, September 2019, Wiley

    Professor Rienzi A Diaz Navarro, Professor John GF Cleland

  114. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology

    Article • European Journal of Heart Failure, August 2019, Wiley

    Professor John GF Cleland

  115. Effects of Serelaxin in Patients with Acute Heart Failure

    Article • New England Journal of Medicine, August 2019, New England Journal of Medicine (NEJM/MMS)

    Professor John GF Cleland

  116. Implantable device monitoring versus usual care for managing individuals with heart failure

    Article • Cochrane Database of Systematic Reviews, August 2019, Wiley

    Professor John GF Cleland

  117. Myocardial Dysfunction and Coronary Artery Disease as Therapeutic Targets in Heart Failure

    Article • Circulation, August 2019, Wolters Kluwer Health

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  118. Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease

    Article • Circulation, August 2019, Wolters Kluwer Health

    Professor John GF Cleland

  119. Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?

    Article • European Heart Journal, August 2019, Oxford University Press (OUP)

    Professor John GF Cleland

  120. Oral modified release morphine for breathlessness in chronic heart failure: a randomized placebo‐controlled trial

    Article • ESC Heart Failure, August 2019, Wiley

    Professor John GF Cleland

  121. Prevalence and Incidence of Atrial Fibrillation in Ambulatory Patients with Heart Failure

    Article • The American Journal of Cardiology, August 2019, Elsevier

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  122. Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure – A multicenter propensity score matched analysis

    Article • International Journal of Cardiology, August 2019, Elsevier

    Professor John GF Cleland

  123. Outcome in Dilated Cardiomyopathy Related to the Extent, Location, and Pattern of Late Gadolinium Enhancement

    Article • JACC Cardiovascular Imaging, August 2019, Elsevier

    Professor John GF Cleland

  124. Geographical location affects the levels and association of trimethylamine N‐oxide with heart failure mortality in BIOSTAT‐CHF: a post‐hoc analysis

    Article • European Journal of Heart Failure, July 2019, Wiley

    Professor John GF Cleland

  125. High sensitivity C-Reactive Protein in Chronic Heart Failure: Patient Characteristics, Phenotypes and Mode of Death

    Article • Cardiovascular Research, July 2019, Oxford University Press (OUP)

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  126. Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy

    Article • Heart, July 2019, BMJ

    Professor John GF Cleland

  127. New perspectives and future directions in the treatment of heart failure

    Article • Heart Failure Reviews, July 2019, Springer Science + Business Media

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  128. The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure

    Article • Clinical Research in Cardiology, July 2019, Springer Science + Business Media

    Professor John GF Cleland

  129. Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure

    Article • JAMA Cardiology, July 2019, American Medical Association (AMA)

    Professor John GF Cleland

  130. When can heart failure treatment be stopped safely? – Authors' reply

    Article • The Lancet, July 2019, Elsevier

    Professor John GF Cleland

  131. The shocking lack of evidence for implantable cardioverter defibrillators for heart failure; with or without cardiac resynchronization

    Article • European Heart Journal, June 2019, Oxford University Press (OUP)

    Professor John GF Cleland

  132. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial

    Article • European Heart Journal, June 2019, Oxford University Press (OUP)

    Dr Joao Pedro Ferreira, Professor John GF Cleland

  133. Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure

    Article • European Journal of Heart Failure, June 2019, Wiley

    Professor John GF Cleland

  134. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

    Article • Kidney International, June 2019, Elsevier

    Dr Debasish Banerjee, Professor John GF Cleland

  135. Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm

    Article • JAMA Cardiology, June 2019, American Medical Association (AMA)

    Professor John GF Cleland

  136. Characteristics and outcome of acute heart failure patients according to the severity of peripheral oedema

    Article • International Journal of Cardiology, June 2019, Elsevier

    Professor John GF Cleland

  137. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations

    Article • European Journal of Heart Failure, June 2019, Wiley

    Professor John GF Cleland

  138. Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure: A cohort study of 93,000 UK patients

    Article • PLoS Medicine, May 2019, PLOS

    Professor John GF Cleland

  139. The clinical significance of interleukin‐6 in heart failure: results from the BIOSTAT‐CHF study

    Article • European Journal of Heart Failure, May 2019, Wiley

    Professor John GF Cleland

  140. Erratum to ‘The role of angiotensin receptor–neprilysin inhibitors in cardiovascular disease—existing evidence, knowledge gaps, and future directions' [Eur J Heart Fail 2018;20:963–972]

    Article • European Journal of Heart Failure, May 2019, Wiley

    Professor John GF Cleland

  141. Prevention or Procrastination for Heart Failure?

    Article • Journal of the American College of Cardiology, May 2019, Elsevier

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  142. Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure

    Article • Circulation Heart Failure, May 2019, Wolters Kluwer Health

    Dr Joao Pedro Ferreira, Professor John GF Cleland

  143. The rise and fall of aspirin in the primary prevention of cardiovascular disease

    Article • The Lancet, May 2019, Elsevier

    Professor John GF Cleland

  144. Does rhythm matter in acute heart failure? An insight from the British Society for Heart Failure National Audit

    Article • Clinical Research in Cardiology, April 2019, Springer Science + Business Media

    Professor John GF Cleland

  145. Clinical and prognostic association of total atrial conduction time in patients with heart failure

    Article • Journal of Cardiovascular Medicine, April 2019, Wolters Kluwer Health

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  146. Valuing health-related quality of life in heart failure: a systematic review of methods to derive quality-adjusted life years (QALYs) in trial-based cost–utility analyses

    Article • Heart Failure Reviews, March 2019, Springer Science + Business Media

    Professor John GF Cleland

  147. Bio‐adrenomedullin as a marker of congestion in patients with new‐onset and worsening heart failure

    Article • European Journal of Heart Failure, March 2019, Wiley

    Professor John GF Cleland

  148. Added value of frailty and social support in predicting risk of 30-day unplanned re-admission or death for patients with heart failure: An analysis from OPERA-HF

    Article • International Journal of Cardiology, March 2019, Elsevier

    Professor John GF Cleland

  149. Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe

    Article • Heart, February 2019, BMJ

    Professor John GF Cleland

  150. The year in cardiology 2018: heart failure

    Article • European Heart Journal, February 2019, Oxford University Press (OUP)

    Professor John GF Cleland

  151. Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology

    Article • European Journal of Heart Failure, February 2019, Wiley

    Professor John GF Cleland, Manuel Mayr

  152. Burden of medical co‐morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy

    Article • European Journal of Heart Failure, January 2019, Wiley

    Professor John GF Cleland

  153. Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure

    Article • European Journal of Heart Failure, January 2019, Wiley

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  154. Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation

    Article • Clinical Research in Cardiology, January 2019, Springer Science + Business Media

    Professor John GF Cleland

  155. Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study

    Article • European Journal of Heart Failure, January 2019, Wiley

    Dr Joao Pedro Ferreira, Professor John GF Cleland

  156. Percutaneous haemodynamic and renal support in patients presenting with decompensated heart failure: A multi-centre efficacy study using the Reitan Catheter Pump (RCP)

    Article • International Journal of Cardiology, January 2019, Elsevier

    Professor John GF Cleland

  157. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial

    Article • The Lancet, January 2019, Elsevier

    Professor John GF Cleland

  158. Novel endotypes in heart failure: effects on guideline-directed medical therapy

    Article • European Heart Journal, December 2018, Oxford University Press (OUP)

    Professor John GF Cleland

  159. Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin

    Article • Indian Heart Journal, December 2018, Elsevier

    Professor John GF Cleland

  160. Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure

    Article • Clinical Proteomics, November 2018, Springer Science + Business Media

    Professor John GF Cleland

  161. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction

    Article • International Journal of Cardiology, November 2018, Elsevier

    Professor John GF Cleland

  162. Association with outcomes and response to treatment of trimethylamine N‐oxide in heart failure: results from BIOSTAT‐CHF

    Article • European Journal of Heart Failure, October 2018, Wiley

    Professor John GF Cleland

  163. Mode of presentation and mortality amongst patients hospitalized with heart failure? A report from the First Euro Heart Failure Survey

    Article • Clinical Research in Cardiology, October 2018, Springer Science + Business Media

    Professor John GF Cleland

  164. Treatments targeting inotropy

    Article • European Heart Journal, October 2018, Oxford University Press (OUP)

    Professor Dietmar J. Manstein, Professor John GF Cleland

  165. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease

    Article • New England Journal of Medicine, October 2018, New England Journal of Medicine (NEJM/MMS)

    Professor John GF Cleland

  166. Dynamic risk stratification using serial measurements of plasma concentrations of natriuretic peptides in patients with heart failure

    Article • International Journal of Cardiology, October 2018, Elsevier

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  167. One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial

    Article • JAMA Cardiology, October 2018, American Medical Association (AMA)

    Professor John GF Cleland

  168. Absence of Myocardial Fibrosis Predicts Favorable Long-Term Survival in New-Onset Heart Failure

    Article • Circulation Cardiovascular Imaging, September 2018, Wolters Kluwer Health

    Professor John GF Cleland

  169. Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction

    Article • Journal of the American College of Cardiology, September 2018, Elsevier

    Professor John GF Cleland

  170. Telehealth: delivering high-quality care for heart failure

    Article • The Lancet, September 2018, Elsevier

    Professor John GF Cleland

  171. 2018 ESC/ESH Guidelines for the management of arterial hypertension

    Article • European Heart Journal, August 2018, Oxford University Press (OUP)

    Professor marija B Vavlukis, Prof HECTOR BUENO, Professor John GF Cleland

  172. Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction

    Article • European Heart Journal, August 2018, Oxford University Press (OUP)

    Professor John GF Cleland

  173. Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure

    Article • Heart, August 2018, BMJ

    Dr Joao Pedro Ferreira, Professor John GF Cleland

  174. Mortality after admission for heart failure in the UK compared with Japan

    Article • Open Heart, August 2018, BMJ

    Professor John GF Cleland

  175. Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life

    Article • Clinical Research in Cardiology, July 2018, Springer Science + Business Media

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  176. Prevalence and determinants of hypertension in apparently healthy schoolchildren in India: A multi-center study

    Article • European Journal of Preventive Cardiology, July 2018, SAGE Publications

    Professor John GF Cleland

  177. Role of immunomodulation on heart functiom following heart attack

    Article • Cardiovascular Research, July 2018, Oxford University Press (OUP)

    Dr Habib Khan, Professor John GF Cleland

  178. Rationale and design of the randomized multicentre His Optimized Pacing Evaluated for Heart Failure (HOPE-HF) trial

    Article • ESC Heart Failure, July 2018, Wiley

    Professor John GF Cleland

  179. Methodological Shortcomings of Wrist-Worn Heart Rate Monitors Validations

    Article • Journal of Medical Internet Research, July 2018, JMIR Publications Inc.

    Professor John GF Cleland

  180. Waist-to-hip ratio and mortality in heart failure

    Article • European Journal of Heart Failure, July 2018, Wiley

    Professor John GF Cleland

  181. Losing Track by Tracking Speckles

    Article • JACC Cardiovascular Imaging, July 2018, Elsevier

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  182. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial

    Article • Circulation Heart Failure, July 2018, Wolters Kluwer Health

    Professor John GF Cleland

  183. Body mass index and all-cause mortality in heart failure patients with normal and reduced ventricular ejection fraction: a dose–response meta-analysis

    Article • Clinical Research in Cardiology, June 2018, Springer Science + Business Media

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  184. Psychosocial factors and mortality in patients with heart failure: reply

    Article • European Journal of Heart Failure, June 2018, Wiley

    Professor John GF Cleland

  185. Sex- and age-based differences in the natural history and outcome of dilated cardiomyopathy

    Article • European Journal of Heart Failure, June 2018, Wiley

    Professor John GF Cleland

  186. Prevalence and Prognostic Significance of Malnutrition Using 3 Scoring Systems Among Outpatients With Heart Failure

    Article • JACC Heart Failure, June 2018, Elsevier

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  187. Validation of U.S. mortality prediction models for hospitalized heart failure in the United Kingdom and Japan

    Article • European Journal of Heart Failure, May 2018, Wiley

    Professor John GF Cleland

  188. Outcome of hospitalised heart failure in Japan and the United Kingdom stratified by plasma N-terminal pro-B-type natriuretic peptide

    Article • Clinical Research in Cardiology, May 2018, Springer Science + Business Media

    Professor John GF Cleland

  189. Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey)

    Article • The American Journal of Cardiology, May 2018, Elsevier

    Dr. Elton AMP Dudink, Professor John GF Cleland

  190. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure

    Article • International Journal of Cardiology, May 2018, Elsevier

    Professor John GF Cleland

  191. Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion

    Article • Circulation Heart Failure, May 2018, Wolters Kluwer Health

    Professor John GF Cleland

  192. Combined use of lung ultrasound, B-type natriuretic peptide, and echocardiography for outcome prediction in patients with acute HFrEF and HFpEF

    Article • Clinical Research in Cardiology, March 2018, Springer Science + Business Media

    Professor John GF Cleland

  193. Acute heart failure: lessons learned, roads ahead

    Article • European Journal of Heart Failure, March 2018, Wiley

    Prof HECTOR BUENO, Professor John GF Cleland

  194. An electronic health records cohort study on heart failure following myocardial infarction in England: incidence and predictors

    Article • BMJ Open, March 2018, BMJ

    Professor John GF Cleland

  195. Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes

    Article • European Journal of Heart Failure, February 2018, Wiley

    Professor John GF Cleland

  196. The role of angiotensin receptor–neprilysin inhibitors in cardiovascular disease—existing evidence, knowledge gaps, and future directions

    Article • European Journal of Heart Failure, February 2018, Wiley

    Professor John GF Cleland

  197. CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients—who is doing what to whom and how?

    Article • European Journal of Heart Failure, February 2018, Wiley

    Professor John GF Cleland

  198. Methodological Shortcomings of Wrist-Worn Heart Rate Monitors Validations (Preprint)

    Article • February 2018, JMIR Publications Inc.

    Professor John GF Cleland

  199. Increased blood lactate is prevalent and identifies poor prognosis in patients with acute heart failure without overt peripheral hypoperfusion

    Article • European Journal of Heart Failure, February 2018, Wiley

    Professor John GF Cleland

  200. Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF

    Article • European Journal of Heart Failure, January 2018, Wiley

    Professor John GF Cleland

  201. Prognostic value of psychosocial factors for first and recurrent hospitalizations and mortality in heart failure patients: insights from the OPERA-HF study

    Article • European Journal of Heart Failure, January 2018, Wiley

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  202. The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis

    Article • European Journal of Heart Failure, January 2018, Wiley

    Professor John GF Cleland

  203. Estimated peak functional capacity: an accurate method for assessing change in peak oxygen consumption after cardiac rehabilitation?

    Article • Clinical Physiology and Functional Imaging, August 2017, Wiley

    Dr simon nichols, Professor John GF Cleland

  204. Coronary angiography in worsening heart failure: determinants, findings and prognostic implications

    Article • Heart, August 2017, BMJ

    Dr Joao Pedro Ferreira, Professor John GF Cleland

  205. Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study

    Article • European Heart Journal - Cardiovascular Pharmacotherapy, May 2017, Oxford University Press (OUP)

    Professor John GF Cleland

  206. An m-Health system for education and motivation in cardiac rehabilitation: the experience of HeartCycle guided exercise

    Article • Journal of Telemedicine and Telecare, March 2017, SAGE Publications

    Dario Salvi, Professor John GF Cleland

  207. Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS

    Article • Journal of Cardiac Failure, October 2016, Elsevier

    Professor john j mcmurray, Professor John GF Cleland

  208. Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients

    Article • International Journal of Cardiology, February 2016, Elsevier

    Professor John GF Cleland

  209. MicroRNAs relate to early worsening of renal function in patients with acute heart failure

    Article • International Journal of Cardiology, January 2016, Elsevier

    Professor John GF Cleland

  210. Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction

    Article • European Journal of Heart Failure, December 2015, Wiley

    Professor john j mcmurray, Professor John GF Cleland

  211. Plasma kidney injury molecule‐1 in heart failure: renal mechanisms and clinical outcome

    Article • European Journal of Heart Failure, October 2015, Wiley

    Professor John GF Cleland

  212. A personalised mobile-based home monitoring system for heart failure: The SUPPORT-HF Study

    Article • International Journal of Medical Informatics, October 2015, Elsevier

    Dr Andreas K Triantafyllidis, Professor John GF Cleland

  213. A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model

    Article • Heart Rhythm, October 2015, Elsevier

    Professor John GF Cleland

  214. Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic review

    Article • International Journal of Cardiology, October 2015, Elsevier

    Professor John GF Cleland, Professor Ashraf Fawzy Nabhan

  215. Abordaje multidisciplinario en pacientes hospitalizados por insuficiencia cardiaca

    Article • Revista Española de Cardiología, October 2015, Elsevier

    Professor John GF Cleland

  216. Should β-Blockers Be Used in Patients With Heart Failure and Atrial Fibrillation?

    Article • Clinical Therapeutics, October 2015, Elsevier

    Professor John GF Cleland

  217. Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial

    Article • Nephrology Dialysis Transplantation, September 2015, Oxford University Press (OUP)

    Professor John GF Cleland

  218. Signature of circulating microRNAs in patients with acute heart failure

    Article • European Journal of Heart Failure, September 2015, Wiley

    Professor John GF Cleland

  219. Development of a Human Model for the Study of Effects of Hypoxia, Exercise, and Sildenafil on Cardiac and Vascular Function in Chronic Heart Failure

    Article • Journal of Cardiovascular Pharmacology, September 2015, Wolters Kluwer Health

    Professor John GF Cleland

  220. Cardiac Resynchronization Therapy Update: Evolving Indications, Expanding Benefit?

    Article • Current Cardiology Reports, August 2015, Springer Science + Business Media

    Professor John GF Cleland

  221. Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)

    Article • PLoS ONE, August 2015, PLOS

    Professor john j mcmurray, Professor John GF Cleland

  222. A combined clinical and biomarker approach to predict diuretic response in acute heart failure

    Article • Clinical Research in Cardiology, August 2015, Springer Science + Business Media

    Professor John GF Cleland

  223. Adherence to self-care in patients with heart failure in the HeartCycle study

    Article • Patient Preference and Adherence, August 2015, Taylor & Francis

    Professor John GF Cleland

  224. QRS morphology as a predictor of the response to cardiac resynchronisation therapy: fact or fashion?

    Article • Heart, July 2015, BMJ

    Professor John GF Cleland

  225. Reflections on EchoCRT: sound guidance on QRS duration and morphology for CRT?: Figure 1

    Article • European Heart Journal, July 2015, European Society of Cardiology

    Professor John GF Cleland

  226. Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial

    Article • European Journal of Heart Failure, June 2015, Wiley

    Dr Robert John Mentz, Professor John GF Cleland

  227. Heart failure with preserved ejection fraction: uncertainties and dilemmas

    Article • European Journal of Heart Failure, June 2015, Wiley

    Professor John GF Cleland

  228. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro–B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction

    Article • JACC Heart Failure, June 2015, Elsevier

    Professor john j mcmurray, Professor John GF Cleland

  229. Prognostic significance of ultrasound-assessed jugular vein distensibility in heart failure

    Article • Heart, May 2015, BMJ

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  230. The Obesity Paradox in Type 2 Diabetes Mellitus: Relationship of Body Mass Index to Prognosis

    Article • Annals of Internal Medicine, May 2015, American College of Physicians

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  231. Worsening Heart Failure Following Admission for Acute Heart Failure

    Article • JACC Heart Failure, May 2015, Elsevier

    Professor John GF Cleland

  232. Rationale and design of a randomized, double‐blind, event‐driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and si...

    Article • European Journal of Heart Failure, April 2015, Wiley

    Dr Roger M Mills, Professor John GF Cleland

  233. The relationship of QRS morphology with cardiac structure and function in patients with heart failure

    Article • Clinical Research in Cardiology, April 2015, Springer Science + Business Media

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  234. The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most?

    Article • European Heart Journal, April 2015, European Society of Cardiology

    Professor John GF Cleland

  235. When Is it Appropriate to Withdraw Cardiac Resynchronization Therapy? Guesses and Evidence ∗

    Article • JACC Heart Failure, April 2015, Elsevier

    Professor John GF Cleland

  236. If home telemonitoring reduces mortality in heart failure, is this just due to better guideline-based treatment?

    Article • Journal of Telemedicine and Telecare, March 2015, SAGE Publications

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  237. International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT‐HF): rationale for and design of a global registry

    Article • European Journal of Heart Failure, March 2015, Wiley

    Professor John GF Cleland

  238. Update on management of heart failure with preserved ejection fraction

    Article • Current Opinion in Cardiology, March 2015, Wolters Kluwer Health

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  239. Prescribing Patterns to Optimize Heart Rate

    Article • JACC Heart Failure, March 2015, Elsevier

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  240. Is the Epidemic of Heart Disease Really Over or Just Evolving?

    Article • The American Journal of Medicine, March 2015, Elsevier

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  241. Acute Heart Failure in the Elderly: Differences in Clinical Characteristics, Outcomes, and Prognostic Factors in the VERITAS Study

    Article • Journal of Cardiac Failure, March 2015, Elsevier

    Professor john j mcmurray, Professor John GF Cleland

  242. Bone marrow iron depletion is common in patients with coronary artery disease

    Article • International Journal of Cardiology, March 2015, Elsevier

    Professor John GF Cleland

  243. The Effect of Carvedilol on B-Type Natriuretic Peptide and Cardiac Function in Patients with Heart Failure and Persistent Atrial Fibrillation

    Article • Cardiology, January 2015, Karger Publishers

    Professor John GF Cleland

  244. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction

    Article • European Journal of Heart Failure, December 2014, Wiley

    Professor john j mcmurray, Professor John GF Cleland

  245. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis

    Article • The Lancet, December 2014, Elsevier

    Professor Giuseppe M C Rosano, Professor John GF Cleland

  246. Breathlessness at rest is not the dominant presentation of patients admitted with heart failure

    Article • European Journal of Heart Failure, November 2014, Wiley

    Professor John GF Cleland

  247. Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial

    Article • European Journal of Heart Failure, November 2014, Wiley

    Professor Marco Metra, Professor John GF Cleland

  248. European Cardiac Resynchronization Therapy Survey II: rationale and design

    Article • EP Europace, November 2014, European Society of Cardiology

    Professor John GF Cleland

  249. Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study

    Article • European Journal of Heart Failure, November 2014, Wiley

    Professor john j mcmurray, Professor John GF Cleland

  250. Left atrial function measured by cardiac magnetic resonance imaging in patients with heart failure: clinical associations and prognostic value

    Article • European Heart Journal, October 2014, European Society of Cardiology

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  251. Charting a Roadmap for Heart Failure Biomarker Studies

    Article • JACC Heart Failure, October 2014, Elsevier

    Dr Robert John Mentz, Professor John GF Cleland

  252. Lipid-Modifying Treatments for Heart Failure

    Article • Heart Failure Clinics, October 2014, Elsevier

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  253. Does Speckle Tracking Really Improve Diagnosis and Risk Stratification in Patients With HF With Normal EF?

    Article • Journal of the American College of Cardiology, October 2014, Elsevier

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  254. Classification of a real live heart failure clinical dataset- Is TAN Bayes better than other Bayes?

    Article • October 2014, Institute of Electrical & Electronics Engineers (IEEE)

    Professor John GF Cleland

  255. Heart ‘omics’ in AGEing (HOMAGE): design, research objectives and characteristics of the common database

    Article • Journal of Biomedical Research, September 2014, Journal of Biomedical Research

    Professor John GF Cleland

  256. Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)

    Article • European Heart Journal, September 2014, European Society of Cardiology

    Professor john j mcmurray, Professor John GF Cleland

  257. Is the Way to a Man’s Heart Through His Stomach?

    Article • Journal of the American College of Cardiology, September 2014, Elsevier

    Professor John GF Cleland

  258. Exercise Capacity and Mortality in Patients With Ischemic Left Ventricular Dysfunction Randomized to Coronary Artery Bypass Graft Surgery or Medical Therapy

    Article • JACC Heart Failure, August 2014, Elsevier

    Professor John GF Cleland

  259. The utility of novel non-invasive technologies for remote hemodynamic monitoring in chronic heart failure

    Article • Expert Review of Cardiovascular Therapy, July 2014, Taylor & Francis

    Professor John GF Cleland

  260. Remote telemonitoring for patients with heart failure: might monitoring pulmonary artery pressure become routine?

    Article • Expert Review of Cardiovascular Therapy, July 2014, Taylor & Francis

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  261. Clinical Trials in Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction

    Article • Heart Failure Clinics, July 2014, Elsevier

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  262. Use of cumulative information estimations for risk assessment of heart failure patients

    Article • July 2014, Institute of Electrical & Electronics Engineers (IEEE)

    Professor John GF Cleland

  263. Telemonitoring in heart failure: Big Brother watching over you

    Article • Heart Failure Reviews, June 2014, Springer Science + Business Media

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  264. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure

    Article • European Heart Journal, June 2014, European Society of Cardiology

    Professor John GF Cleland

  265. The remarkable effect of ivabradine in two adolescents with dilated cardiomyopathy

    Article • Clinical Research in Cardiology, June 2014, Springer Science + Business Media

    Professor John GF Cleland

  266. Effect of Rosuvastatin on Repeat Heart Failure Hospitalizations

    Article • JACC Heart Failure, June 2014, Elsevier

    Professor john j mcmurray, Professor John GF Cleland

  267. Is Heart Rate Important for Patients With Heart Failure in Atrial Fibrillation?

    Article • JACC Heart Failure, June 2014, Elsevier

    Professor John GF Cleland

  268. The relation between repeated 6-minute walk test performance and outcome in patients with chronic heart failure

    Article • Annals of Physical and Rehabilitation Medicine, June 2014, Elsevier

    Professor John GF Cleland

  269. International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial

    Article • European Journal of Heart Failure, April 2014, Wiley

    Dr Robert John Mentz, Professor John GF Cleland

  270. Developing Therapies for Heart Failure With Preserved Ejection Fraction

    Article • JACC Heart Failure, April 2014, Elsevier

    Professor Giuseppe M C Rosano, Professor john j mcmurray, Professor John GF Cleland

  271. Fatigue as a Predictor of Outcome in Patients With Heart Failure

    Article • JACC Heart Failure, April 2014, Elsevier

    Professor john j mcmurray, Professor John GF Cleland

  272. Issues in the Mining of Heart Failure Datasets

    Article • International Journal of Automation and Computing, April 2014, Springer Science + Business Media

    Professor John GF Cleland

  273. Is age a factor in the success or failure of remote monitoring in heart failure? Telemonitoring and structured telephone support in elderly heart failure patients

    Article • European Journal of Cardiovascular Nursing, March 2014, SAGE Publications

    Professor John GF Cleland

  274. Xanthine Oxidase Inhibition for the Treatment of Cardiovascular Disease: A Systematic Review and Meta-Analysis

    Article • Cardiovascular Therapeutics, March 2014, Wiley

    Professor John GF Cleland

  275. Decongestion in acute heart failure

    Article • European Journal of Heart Failure, March 2014, Wiley

    Dr Robert John Mentz, Professor John GF Cleland

  276. Aspirin for Heart Failure

    Article • Circulation Heart Failure, March 2014, Wolters Kluwer Health

    Professor John GF Cleland

  277. Diuretic response in acute heart failure: clinical characteristics and prognostic significance

    Article • European Heart Journal, February 2014, European Society of Cardiology

    Professor Adriaan A Voors, Professor John GF Cleland

  278. Development of a composite model derived from cardiopulmonary exercise tests to predict mortality risk in patients with mild-to-moderate heart failure

    Article • Heart, February 2014, BMJ

    Professor John GF Cleland

  279. Thyroid-Stimulating Hormone and Clinical Outcomes

    Article • JACC Heart Failure, February 2014, Elsevier

    Professor john j mcmurray, Professor John GF Cleland

  280. The in vitro stability of novel cardiovascular and sepsis biomarkers at ambient temperature

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2014, De Gruyter

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  281. Revisiting a classical clinical sign: Jugular venous ultrasound

    Article • International Journal of Cardiology, January 2014, Elsevier

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  282. Guía de práctica clínica de la ESC 2013 sobre estimulación cardiaca y terapia de resincronización cardiaca

    Article • Revista Española de Cardiología, January 2014, Elsevier

    Professor John GF Cleland

  283. Definitions of Outcome, Response and Effect in Imaging Research to Avoid Confusion

    Article • JACC Cardiovascular Imaging, January 2014, Elsevier

    Professor John GF Cleland

  284. Predictors of Postdischarge Outcomes From Information Acquired Shortly After Admission for Acute Heart Failure

    Article • Circulation Heart Failure, January 2014, Wolters Kluwer Health

    Professor John GF Cleland

  285. Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure

    Article • Circulation Heart Failure, January 2014, Wolters Kluwer Health

    Professor John GF Cleland

  286. The Long-Term Prognostic Significance of 6-Minute Walk Test Distance in Patients with Chronic Heart Failure

    Article • BioMed Research International, January 2014, Hindawi Publishing Corporation

    Professor John GF Cleland

  287. Impact of aspirin and statins on long-term survival in patients hospitalized with acute myocardial infarction complicated by heart failure: an analysis of 1706 patients

    Article • European Journal of Heart Failure, December 2013, Wiley

    Professor John GF Cleland

  288. Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties

    Article • European Journal of Heart Failure, December 2013, Wiley

    Professor Giuseppe M C Rosano, Professor John GF Cleland

  289. Sex-specific acute heart failure phenotypes and outcomes from PROTECT

    Article • European Journal of Heart Failure, December 2013, Wiley

    Professor John GF Cleland

  290. The C-CURE Randomized Clinical Trial (Cardiopoietic stem Cell therapy in heart failURE)

    Article • Journal of the American College of Cardiology, December 2013, Elsevier

    Professor John GF Cleland

  291. Global longitudinal strain in patients with suspected heart failure and a normal ejection fraction: does it improve diagnosis and risk stratification?

    Article • The International Journal of Cardiovascular Imaging, October 2013, Springer Science + Business Media

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  292. Iron Status and Survival in Diabetic Patients With Coronary Artery Disease

    Article • Diabetes Care, October 2013, American Diabetes Association

    Professor John GF Cleland

  293. Case Selection for Cardiac Resynchronization in Atrial Fibrillation

    Article • Heart Failure Clinics, October 2013, Elsevier

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  294. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document

    Article • European Journal of Heart Failure, October 2013, Wiley

    Professor Giuseppe M C Rosano, Professor john j mcmurray, Professor John GF Cleland

  295. Prognostic value of CXCL16 in patients with left ventricular systolic dysfunction and heart failure

    Article • International Journal of Cardiology, October 2013, Elsevier

    Professor john j mcmurray, Professor John GF Cleland

  296. The effectiveness of enhanced external counterpulsation (EECP) in patients suffering from chronic refractory angina previously treated with transmyocardial laser revascularisation

    Article • International Journal of Cardiology, October 2013, Elsevier

    Professor John GF Cleland

  297. Wytyczne ESC dotyczące stymulacji serca i terapii resynchronizującej w 2013 roku

    Article • Kardiologia Polska, September 2013, Polskie Towarzystwo Kardiologiczne

    Professor John GF Cleland

  298. Diabetes, aliskiren, and heart failure: let's bring ASTRONAUT down to earth

    Article • European Heart Journal, September 2013, European Society of Cardiology

    Professor John GF Cleland

  299. Hypoglycaemia in diabetic patients: highly undesirable by cardiologists

    Article • European Heart Journal, September 2013, European Society of Cardiology

    Professor John GF Cleland

  300. Does cirrhotic cardiomyopathy exist? 50 years of uncertainty

    Article • Clinical Research in Cardiology, September 2013, Springer Science + Business Media

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  301. Not all systematic reviews are systematic: a meta-review of the quality of systematic reviews for non-invasive remote monitoring in heart failure

    Article • Journal of Telemedicine and Telecare, September 2013, SAGE Publications

    Professor John GF Cleland

  302. Telemonitoring after discharge from hospital with heart failure: cost-effectiveness modelling of alternative service designs

    Article • BMJ Open, September 2013, BMJ

    Professor John GF Cleland

  303. Is aspirin useful in primary prevention?

    Article • European Heart Journal, August 2013, European Society of Cardiology

    Professor John GF Cleland

  304. Digoxin Reduces 30-day All-cause Hospital Admission in Older Patients with Chronic Systolic Heart Failure

    Article • The American Journal of Medicine, August 2013, Elsevier

    Professor john j mcmurray, Dr. Richard M Allman, Professor John GF Cleland

  305. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure

    Article • European Heart Journal, July 2013, European Society of Cardiology

    Professor John GF Cleland

  306. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy

    Article • European Heart Journal, June 2013, European Society of Cardiology

    Professor Luigi P. Badano, Prof HECTOR BUENO, Professor John GF Cleland

  307. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Associati...

    Article • EP Europace, June 2013, European Society of Cardiology

    Prof HECTOR BUENO, Professor Luigi P. Badano, Professor John GF Cleland

  308. Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis

    Article • Heart, May 2013, BMJ

    Professor John GF Cleland

  309. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial

    Article • European Journal of Heart Failure, May 2013, Wiley

    Professor john j mcmurray, Professor John GF Cleland

  310. Effects of reducing inspired oxygen concentration for one hour in patients with chronic heart failure: implications for air travel

    Article • European Journal of Heart Failure, May 2013, Wiley

    Professor John GF Cleland

  311. Improving Quality of Life and Functional Capacity in Atrial Fibrillation and Congestive Heart Failure

    Article • Journal of the American College of Cardiology, May 2013, Elsevier

    Professor John GF Cleland

  312. Influence of Crossover on Mortality in a Randomized Study of Revascularization in Patients With Systolic Heart Failure and Coronary Artery Disease

    Article • Circulation Heart Failure, May 2013, Wolters Kluwer Health

    Professor John GF Cleland

  313. Interplay Between Right Ventricular Function and Cardiac Resynchronization Therapy

    Article • Journal of the American College of Cardiology, May 2013, Elsevier

    Professor John GF Cleland

  314. The Predictive Value of Short-Term Changes in Hemoglobin Concentration in Patients Presenting With Acute Decompensated Heart Failure

    Article • Journal of the American College of Cardiology, May 2013, Elsevier

    Professor John GF Cleland

  315. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial

    Article • European Heart Journal, April 2013, European Society of Cardiology

    Professor John GF Cleland

  316. Why Does CRT Reduce the Risk of Arrhythmias?

    Article • JACC Cardiovascular Imaging, April 2013, Elsevier

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  317. Renal Sympathetic Denervation Therapy for Resistant Hypertension

    Article • Circulation Cardiovascular Interventions, April 2013, Wolters Kluwer Health

    Professor John GF Cleland

  318. Fish Oil vs Olive Oil for Postoperative Atrial Fibrillation

    Article • JAMA, March 2013, American Medical Association (AMA)

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  319. Repeat Dose Opioids May Be Effective for Breathlessness in Chronic Heart Failure if Given for Long Enough

    Article • Journal of Palliative Medicine, March 2013, Mary Ann Liebert Inc

    Professor John GF Cleland

  320. Defining Diastolic Heart Failure and Identifying Effective Therapies

    Article • JAMA, February 2013, American Medical Association (AMA)

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  321. Medical Management of Stable Coronary Atherosclerosis

    Article • Current Atherosclerosis Reports, February 2013, Springer Science + Business Media

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  322. Identifying patients at risk of death or hospitalisation due to worsening heart failure using decision tree analysis: Evidence from the Trans-European Network-Home-Care Management System (TEN-HMS) Study

    Article • International Journal of Cardiology, February 2013, Elsevier

    Professor John GF Cleland

  323. Causes and treatment of oedema in patients with heart failure

    Article • Nature Reviews Cardiology, January 2013, Springer Science + Business Media

    Professor John GF Cleland

  324. A Meta-Analysis Reporting Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients Without Heart Failure

    Article • Journal of the American College of Cardiology, January 2013, Elsevier

    Professor Giuseppe M C Rosano, Professor John GF Cleland

  325. IVC Diameter in Patients With Chronic Heart Failure

    Article • JACC Cardiovascular Imaging, January 2013, Elsevier

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  326. Sildenafil in Heart Failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design

    Article • European Journal of Heart Failure, January 2013, Wiley

    Professor John GF Cleland

  327. Soluble Glycoprotein 130 Predicts Fatal Outcomes in Chronic Heart Failure: Analysis From the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)

    Article • Circulation Heart Failure, December 2012, Wolters Kluwer Health

    Professor john j mcmurray, Professor John GF Cleland

  328. Influence of step length on 6-minute walk test performance in patients with chronic heart failure

    Article • Physiotherapy, December 2012, Elsevier

    Professor John GF Cleland

  329. Important Differences in Mode of Death Between Men and Women With Heart Failure Who Would Qualify for a Primary Prevention Implantable Cardioverter-Defibrillator

    Article • Circulation, November 2012, Wolters Kluwer Health

    Professor John GF Cleland

  330. An atrial mass

    Article • Journal of Cardiovascular Medicine, November 2012, Wolters Kluwer Health

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  331. Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions

    Article • Heart Failure Reviews, October 2012, Springer Science + Business Media

    Professor John GF Cleland

  332. Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?

    Article • Life Sciences, October 2012, Elsevier

    Professor John GF Cleland

  333. Diagnosis of elderly patients with heart failure

    Article • European Journal of Heart Failure, October 2012, Wiley

    Professor John GF Cleland

  334. Heart failure—does it matter whether LVEF is reduced?

    Article • The Lancet, October 2012, Elsevier

    Professor John GF Cleland

  335. Anticoagulation in heart failure: current status and future direction

    Article • Heart Failure Reviews, September 2012, Springer Science + Business Media

    Professor John GF Cleland

  336. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management

    Article • Heart Rhythm, September 2012, Elsevier

    Professor John GF Cleland

  337. Minimally clinically important difference in chronic breathlessness: Every little helps

    Article • American Heart Journal, August 2012, Elsevier

    Professor John GF Cleland

  338. Standardized Reporting Criteria for Studies Evaluating Suspected Acute Heart Failure Syndromes in the Emergency Department

    Article • Journal of the American College of Cardiology, August 2012, Elsevier

    Professor John GF Cleland

  339. Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target?

    Article • European Journal of Heart Failure, July 2012, Wiley

    Professor John GF Cleland

  340. Renal artery stenosis: an innocent bystander or an independent predictor of worse outcome in patients with chronic heart failure? A magnetic resonance imaging study

    Article • European Journal of Heart Failure, July 2012, Wiley

    Professor John GF Cleland

  341. The PROTECT in‐hospital risk model: 7‐day outcome in patients hospitalized with acute heart failure and renal dysfunction

    Article • European Journal of Heart Failure, June 2012, Wiley

    Dr Robert John Mentz, Professor John GF Cleland

  342. Experiences of air travel in patients with chronic heart failure

    Article • International Journal of Cardiology, June 2012, Elsevier

    Professor John GF Cleland

  343. Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) trial

    Article • European Journal of Heart Failure, June 2012, Wiley

    Professor John GF Cleland

  344. Soluble guanylate cyclase: a potential therapeutic target for heart failure

    Article • Heart Failure Reviews, May 2012, Springer Science + Business Media

    Professor John GF Cleland

  345. Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure

    Article • Heart Failure Reviews, May 2012, Springer Science + Business Media

    Professor John GF Cleland

  346. A comparative study of missing value imputation with multiclass classification for clinical heart failure data

    Article • May 2012, Institute of Electrical & Electronics Engineers (IEEE)

    Professor John GF Cleland

  347. Body mass index is related to the perception of exertional breathlessness in patients presenting with dyspnoea of unknown origin

    Article • International Journal of Cardiology, May 2012, Elsevier

    Professor John GF Cleland

  348. Handling missing values in data mining - A case study of heart failure dataset

    Article • May 2012, Institute of Electrical & Electronics Engineers (IEEE)

    Professor John GF Cleland

  349. Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study

    Article • European Journal of Heart Failure, May 2012, Wiley

    Professor John GF Cleland

  350. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)

    Article • European Heart Journal, April 2012, European Society of Cardiology

    Professor john j mcmurray, Professor John GF Cleland

  351. People with disabilities: the forgotten victims of violence

    Article • The Lancet, April 2012, Elsevier

    Professor John GF Cleland

  352. Role of Antithrombotic Agents in Heart Failure

    Article • Current Cardiology Reports, March 2012, Springer Science + Business Media

    Professor John GF Cleland

  353. Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?

    Article • European Heart Journal, March 2012, European Society of Cardiology

    Professor john j mcmurray, Professor John GF Cleland

  354. Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis

    Article • Heart Failure Reviews, March 2012, Springer Science + Business Media

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  355. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology

    Article • European Journal of Heart Failure, March 2012, Wiley

    Professor john j mcmurray, Professor John GF Cleland

  356. Prevalence of, Associations With, and Prognostic Value of Tricuspid Annular Plane Systolic Excursion (TAPSE) Among Out-Patients Referred for the Evaluation of Heart Failure

    Article • Journal of Cardiac Failure, March 2012, Elsevier

    Professor John GF Cleland

  357. The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment

    Article • Drug Safety, March 2012, Springer Science + Business Media

    Professor John GF Cleland

  358. Targeting myocardial substrate metabolism in heart failure: potential for new therapies

    Article • European Journal of Heart Failure, February 2012, Wiley

    Professor John GF Cleland

  359. Systematic Reporting Bias in Meta-analyses of Trials of Aspirin for the Primary Prevention of Cardiovascular Disease

    Article • The American Journal of Medicine, February 2012, Elsevier

    Professor John GF Cleland

  360. Determinants and Consequences of Renal Function Variations With Aldosterone Blocker Therapy in Heart Failure Patients After Myocardial Infarction

    Article • Circulation, January 2012, Wolters Kluwer Health

    Professor John GF Cleland

  361. Abnormalities of the Ventilatory Equivalent for Carbon Dioxide in Patients with Chronic Heart Failure

    Article • Pulmonary Medicine, January 2012, Hindawi Publishing Corporation

    Professor John GF Cleland

  362. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial

    Article • European Journal of Heart Failure, January 2012, Wiley

    Professor John GF Cleland

  363. The European CRT Survey: 1 year (9-15 months) follow-up results

    Article • European Journal of Heart Failure, January 2012, Wiley

    Professor John GF Cleland

  364. Use of Carotid Intima-Media Thickness Regression to Guide Therapy and Management of Cardiac Risks

    Article • Current Treatment Options in Cardiovascular Medicine, December 2011, Springer Science + Business Media

    Professor John GF Cleland

  365. Clinical trials update from the European Society of Cardiology Meeting 2011: ARISTOTLE, SMART-AV: QLV substudy, SHIFT: echocardiography and quality of life substudies, European CRT Survey, and Basic Science Update

    Article • European Journal of Heart Failure, December 2011, Wiley

    Professor John GF Cleland

  366. Does the physical examination still have a role in patients with suspected heart failure?

    Article • European Journal of Heart Failure, December 2011, Wiley

    Professor John GF Cleland

  367. Right and left bundle branch block as predictors of long-term mortality following myocardial infarction

    Article • European Journal of Heart Failure, December 2011, Wiley

    Professor John GF Cleland

  368. The determinants of clinical outcome and clinical response to CRT are not the same

    Article • Heart Failure Reviews, November 2011, Springer Science + Business Media

    Professor John GF Cleland

  369. Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

    Article • American Heart Journal, November 2011, Elsevier

    Professor john j mcmurray, Professor John GF Cleland

  370. Impact of Serial Troponin Release on Outcomes in Patients With Acute Heart Failure

    Article • Circulation Heart Failure, November 2011, Wolters Kluwer Health

    Professor John GF Cleland

  371. Atherosclerotic disease of the abdominal aorta and its branches: prognostic implications in patients with heart failure

    Article • Heart Failure Reviews, October 2011, Springer Science + Business Media

    Professor John GF Cleland

  372. Clinical trials update from the European Society of Cardiology Heart Failure meeting 2011: TEHAF, WHICH, CARVIVA, and atrial fibrillation in GISSI-HF and EMPHASIS-HF

    Article • European Journal of Heart Failure, October 2011, Wiley

    Professor John GF Cleland

  373. Prevalence of scarred and dysfunctional myocardium in patients with heart failure of ischaemic origin: A cardiovascular magnetic resonance study

    Article • Journal of Cardiovascular Magnetic Resonance, September 2011, Springer Science + Business Media

    Professor John GF Cleland

  374. Increasing knowledge and changing views in cardiac resynchronization therapy

    Article • Heart Failure Reviews, September 2011, Springer Science + Business Media

    Professor John GF Cleland

  375. Limited role for ivabradine in the treatment of chronic heart failure

    Article • Heart, September 2011, BMJ

    Professor John GF Cleland

  376. Clinical assessment of acute heart failure syndromes: emergency department through the early post-discharge period

    Article • Heart, September 2011, BMJ

    Professor John GF Cleland

  377. Short-term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial

    Article • European Journal of Heart Failure, September 2011, Wiley

    Professor David Torgerson, Professor John GF Cleland

  378. Questioning the predictive role of carotid intima–media thickness

    Article • Future Cardiology, September 2011, Future Medicine

    Professor John GF Cleland

  379. The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades

    Article • European Journal of Heart Failure, September 2011, Wiley

    Professor John GF Cleland

  380. Which components of heart failure programmes are effective? A systematic review and meta-analysis of the outcomes of structured telephone support or telemonitoring as the primary component of chronic heart failure management in 8323 patients: Abridged Coc

    Article • European Journal of Heart Failure, September 2011, Wiley

    Professor John GF Cleland

  381. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

    Article • The Lancet, August 2011, Elsevier

    Professor john j mcmurray, Professor John GF Cleland

  382. Clinical trials update from the American College of Cardiology Meeting 2011: STICH, NorthStar, TARGET, and EVEREST II

    Article • European Journal of Heart Failure, July 2011, Wiley

    Professor John GF Cleland

  383. Revascularization for patients with heart failure. Inconsistencies between theory and practice

    Article • European Journal of Heart Failure, July 2011, Wiley

    Professor John GF Cleland

  384. Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction: Findings From the I-PRESERVE Trial

    Article • Circulation Heart Failure, June 2011, Wolters Kluwer Health

    Professor john j mcmurray, Professor John GF Cleland

  385. The Authors' reply

    Article • Heart, June 2011, BMJ

    Professor John GF Cleland

  386. It makes SENSE to take a safer road

    Article • European Heart Journal, May 2011, European Society of Cardiology

    Professor John GF Cleland

  387. Effects of the Adenosine A1 Receptor Antagonist Rolofylline on Renal Function in Patients With Acute Heart Failure and Renal Dysfunction

    Article • Journal of the American College of Cardiology, May 2011, Elsevier

    Professor John GF Cleland

  388. Prognostic significance of different measures of the ventilation-carbon dioxide relation in patients with suspected heart failure

    Article • European Journal of Heart Failure, May 2011, Wiley

    Professor John GF Cleland

  389. Clinical trials update from the American Heart Association Meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT

    Article • European Journal of Heart Failure, April 2011, Wiley

    Dr Pierpaolo Pellicori, Professor John GF Cleland

  390. A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy

    Article • European Heart Journal, April 2011, European Society of Cardiology

    Professor John GF Cleland

  391. Telemonitoring in Patients with Heart Failure

    Article • New England Journal of Medicine, March 2011, New England Journal of Medicine (NEJM/MMS)

    Professor John GF Cleland

  392. Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study

    Article • European Heart Journal, March 2011, European Society of Cardiology

    Professor John GF Cleland

  393. A comparison between monophasic and biphasic defibrillation for the cardioversion of persistent atrial fibrillation in patients with and without heart failure

    Article • International Journal of Cardiology, March 2011, Elsevier

    Professor John GF Cleland

  394. Body mass indices and outcome in patients with chronic heart failure

    Article • European Journal of Heart Failure, February 2011, Wiley

    Professor John GF Cleland

  395. Derivation and validation of a simple clinical risk-model in heart failure based on 6 minute walk test performance and NT-proBNP status – Do we need specificity for sex and beta-blockers?

    Article • International Journal of Cardiology, February 2011, Elsevier

    Professor John GF Cleland

  396. The Heart Failure Revascularisation Trial (HEART)

    Article • European Journal of Heart Failure, February 2011, Wiley

    Professor John GF Cleland

  397. Unmasking the truth

    Article • BMJ Case Reports, January 2011, BMJ

    Professor John GF Cleland

  398. Relationship between right ventricular volumes measured by cardiac magnetic resonance imaging and prognosis in patients with chronic heart failure

    Article • European Journal of Heart Failure, January 2011, Wiley

    Professor John GF Cleland

  399. The national heart failure audit for England and Wales 2008-2009

    Article • Heart, December 2010, BMJ

    Professor John GF Cleland

  400. Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)

    Article • Journal of Cachexia Sarcopenia and Muscle, December 2010, Wiley

    Professor Giuseppe M C Rosano, Professor John GF Cleland

  401. Clinical trials update from the European Society of Cardiology Meeting 2010: SHIFT, PEARL-HF, STAR-heart, and HEBE-III

    Article • European Journal of Heart Failure, November 2010, Wiley

    Professor John GF Cleland

  402. La terapia de resincronización es coste-efectiva

    Article • Revista Española de Cardiología, November 2010, Elsevier

    Professor John GF Cleland

  403. An Entirely Subcutaneous Implantable Cardioverter–Defibrillator

    Article • New England Journal of Medicine, October 2010, New England Journal of Medicine (NEJM/MMS)

    Professor John GF Cleland

  404. Rolofylline, an Adenosine A1−Receptor Antagonist, in Acute Heart Failure

    Article • New England Journal of Medicine, October 2010, New England Journal of Medicine (NEJM/MMS)

    Professor John GF Cleland, Professor Dmitry Zateyshchikov

  405. Coenzyme Q10, Rosuvastatin, and Clinical Outcomes in Heart Failure

    Article • Journal of the American College of Cardiology, October 2010, Elsevier

    Professor john j mcmurray, Professor John GF Cleland

  406. Enlisting the Help of the Largest Health Care Workforce—Patients

    Article • JAMA, September 2010, American Medical Association (AMA)

    Professor John GF Cleland

  407. Editorialists' reply

    Article • BMJ, September 2010, BMJ

    Professor John GF Cleland

  408. Emerging Therapies for Heart Failure

    Article • September 2010, Wiley

    Professor John GF Cleland

  409. Applying evidence-based device care in cardiovascular patients: which patient with heart failure and what device?

    Article • The Journal of the Royal College of Physicians of Edinburgh, September 2010, Royal College of Physicians of Edinburgh

    Professor John GF Cleland

  410. Cardiac output does not limit submaximal exercise capacity in patients with chronic heart failure

    Article • European Journal of Heart Failure, September 2010, Wiley

    Professor John GF Cleland

  411. Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure

    Article • European Heart Journal, August 2010, European Society of Cardiology

    Professor John GF Cleland

  412. Clinical trials update from the European Society of Cardiology Heart Failure Meeting 2010: TRIDENT 1, BENEFICIAL, CUPID, RFA-HF, MUSIC, DUEL, handheld BNP, phrenic nerve stimulation, CHAMPION and CABG with CRT study

    Article • European Journal of Heart Failure, August 2010, Wiley

    Professor John GF Cleland

  413. Calcium supplements in people with osteoporosis

    Article • BMJ, July 2010, BMJ

    Professor John GF Cleland

  414. Letter by Begg et al Regarding Article, “The Effects of Vitamin D Supplementation on Physical Function and Quality of Life in Older Heart Failure Patients: A Randomized Controlled Trial”

    Article • Circulation Heart Failure, July 2010, Wolters Kluwer Health

    Professor John GF Cleland

  415. Clinical trials update from the American College of Cardiology meeting 2010: DOSE, ASPIRE, CONNECT, STICH, STOP-AF, CABANA, RACE II, EVEREST II, ACCORD, and NAVIGATOR

    Article • European Journal of Heart Failure, June 2010, Wiley

    Professor John GF Cleland

  416. Should We Be Trying to Define Responders to Cardiac Resynchronization Therapy?

    Article • JACC Cardiovascular Imaging, May 2010, Elsevier

    Professor John GF Cleland

  417. Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine

    Article • European Journal of Heart Failure, April 2010, Wiley

    Professor john j mcmurray, Professor John GF Cleland

  418. Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study

    Article • European Journal of Heart Failure, April 2010, Wiley

    Professor John GF Cleland

  419. Reply

    Article • Journal of the American College of Cardiology, April 2010, Elsevier

    Professor john j mcmurray, Professor John GF Cleland

  420. Cost-effectiveness of enhanced external counterpulsation (EECP) for the treatment of stable angina in the United Kingdom

    Article • International Journal of Technology Assessment in Health Care, April 2010, Cambridge University Press

    Professor John GF Cleland

  421. Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes: Lessons Learned and Directions Forward

    Article • Circulation Heart Failure, March 2010, Wolters Kluwer Health

    Professor john j mcmurray, Professor John GF Cleland

  422. Long-term aspirin for coronary artery disease: are we being deceived by a biased presentation of the evidence?

    Article • Future Cardiology, March 2010, Future Medicine

    Professor John GF Cleland

  423. Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure - a COMET substudy

    Article • Thrombosis Research, February 2010, Elsevier

    Professor John GF Cleland

  424. Defibrillators—a shocking therapy for cardiomyopathy?

    Article • Nature Reviews Cardiology, February 2010, Springer Science + Business Media

    Professor John GF Cleland

  425. Clinical trials update from the American Heart Association meeting 2009: HEAAL, FAIR-HF, J-CHF, HeartMate II, PACE and a meta-analysis of dose-ranging studies of beta-blockers in heart failure

    Article • European Journal of Heart Failure, January 2010, Wiley

    Professor John GF Cleland

  426. Clinical trials update from the Heart Failure Society of America Meeting 2009: FAST, IMPROVE-HF, COACH galectin-3 substudy, HF-ACTION nuclear substudy, DAD-HF, and MARVEL-1

    Article • European Journal of Heart Failure, January 2010, Wiley

    Professor John GF Cleland

  427. Measurement of breathlessness in clinical trials in patients with chronic heart failure: the need for a standardized approach: a systematic review

    Article • European Journal of Heart Failure, January 2010, Wiley

    Professor John GF Cleland

  428. Lack of Diastolic Reserve in Patients With Heart Failure and Normal Ejection Fraction

    Article • Circulation Heart Failure, January 2010, Wolters Kluwer Health

    Professor John GF Cleland

  429. Predictors of short term mortality in heart failure — Insights from the Euro Heart Failure survey

    Article • International Journal of Cardiology, January 2010, Elsevier

    Professor John GF Cleland

  430. The Atrial Fibrillation Paradox of Heart Failure

    Article • Congestive Heart Failure, January 2010, Wiley

    Professor John GF Cleland

  431. Declining In-Hospital Mortality and Increasing Heart Failure Incidence in Elderly Patients With First Myocardial Infarction

    Article • Journal of the American College of Cardiology, December 2009, Elsevier

    Professor John GF Cleland

  432. Resource Use and Costs of Treatment With Anticoagulation and Antiplatelet Agents: Results of the WATCH Trial Economic Evaluation

    Article • Journal of Cardiac Failure, December 2009, Elsevier

    Professor John GF Cleland

  433. Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE-I, European CRT survey, German pre-SCD II registry, and MADIT-CRT

    Article • European Journal of Heart Failure, November 2009, Wiley

    Professor John GF Cleland

  434. Red cell distribution width: an inexpensive and powerful prognostic marker in heart failure

    Article • European Journal of Heart Failure, November 2009, Wiley

    Professor John GF Cleland

  435. Response to Letter Regarding Article, “Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial”

    Article • Circulation, November 2009, Wolters Kluwer Health

    Professor John GF Cleland

  436. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study

    Article • European Heart Journal, November 2009, European Society of Cardiology

    Professor John GF Cleland

  437. Plasma Concentration of Amino-Terminal Pro-Brain Natriuretic Peptide in Chronic Heart Failure: Prediction of Cardiovascular Events and Interaction With the Effects of Rosuvastatin

    Article • Journal of the American College of Cardiology, November 2009, Elsevier

    Professor john j mcmurray, Professor John GF Cleland

  438. Is taking part in clinical trials good for your health? A cohort study

    Article • European Journal of Heart Failure, October 2009, Wiley

    Professor John GF Cleland

  439. Micronutrient Deficiencies

    Article • Journal of the American College of Cardiology, October 2009, Elsevier

    Professor John GF Cleland

  440. Aspirin in the primary prevention of vascular disease

    Article • The Lancet, September 2009, Elsevier

    Professor John GF Cleland

  441. The European cardiac resynchronization therapy survey

    Article • European Heart Journal, August 2009, European Society of Cardiology

    Professor John GF Cleland

  442. Impact of different diagnostic criteria on the prevalence and prognostic significance of exertional oscillatory ventilation in patients with chronic heart failure

    Article • European Journal of Cardiovascular Prevention & Rehabilitation, August 2009, SAGE Publications

    Professor John GF Cleland

  443. Clinical trials update from the European Society of Cardiology heart failure meeting 2009: CHANCE, B-Convinced, CHAT, CIBIS-ELD, and Signal-HF

    Article • European Journal of Heart Failure, July 2009, Wiley

    Professor John GF Cleland

  444. Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a sub-analysis of the CARE-HF trial

    Article • European Journal of Heart Failure, June 2009, Wiley

    Professor John GF Cleland

  445. Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study

    Article • European Heart Journal, June 2009, European Society of Cardiology

    Professor John GF Cleland

  446. Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group

    Article • American Heart Journal, June 2009, Elsevier

    Professor john j mcmurray, Professor John GF Cleland

  447. Clinical trials update from the American College of Cardiology 2009: ADMIRE-HF, PRIMA, STICH, REVERSE, IRIS, partial ventricular support, FIX-HF-5, vagal stimulation, REVIVAL-3, pre-RELAX-AHF, ACTIVE-A, HF-ACTION, JUPITER, AURORA, and OMEGA

    Article • European Journal of Heart Failure, May 2009, Wiley

    Professor John GF Cleland

  448. Atrial Fibrillation and Heart Failure in Cardiology Practice: Reciprocal Impact and Combined Management From the Perspective of Atrial Fibrillation

    Article • Journal of the American College of Cardiology, May 2009, Elsevier

    Professor John GF Cleland

  449. Long-term left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF trial

    Article • European Journal of Heart Failure, April 2009, Wiley

    Professor John GF Cleland

  450. Obituary to Philip Poole-Wilson 1943-2009

    Article • European Journal of Heart Failure, April 2009, Wiley

    Professor John GF Cleland

  451. Self-rated health and mortality in patients with chronic heart failure

    Article • European Journal of Heart Failure, April 2009, Wiley

    Professor John GF Cleland

  452. Unconventional End Points in Cardiovascular Clinical Trials: Should We Be Moving Away From Morbidity and Mortality?

    Article • Journal of Cardiac Failure, April 2009, Elsevier

    Professor Philippe Gabriel STEG, Professor John GF Cleland

  453. Enhanced external counterpulsation for the treatment of stable angina and heart failure: a systematic review and economic analysis

    Article • Health Technology Assessment, April 2009, National Institute for Health Research

    Professor John GF Cleland

  454. Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure

    Article • Circulation, March 2009, Wolters Kluwer Health

    Professor John GF Cleland

  455. Predicting hospitalization due to worsening heart failure using daily weight measurement: analysis of the Trans-European Network-Home-Care Management System (TEN-HMS) study

    Article • European Journal of Heart Failure, March 2009, Wiley

    Professor John GF Cleland

  456. The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction

    Article • European Journal of Heart Failure, March 2009, Wiley

    Professor John GF Cleland

  457. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study)

    Article • Heart, March 2009, BMJ

    Professor John GF Cleland

  458. Current state of knowledge and experts’ perspective on the subcutaneous implantable cardioverter-defibrillator

    Article • Journal of Interventional Cardiac Electrophysiology, March 2009, Springer Science + Business Media

    Professor John GF Cleland

  459. Effects of cardiac resynchronization therapy on long-term quality of life: An analysis from the CArdiac Resynchronisation-Heart Failure (CARE-HF) study

    Article • American Heart Journal, March 2009, Elsevier

    Professor John GF Cleland

  460. Digoxin

    Article • Circulation Heart Failure, March 2009, Wolters Kluwer Health

    Professor John GF Cleland

  461. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide

    Article • European Journal of Heart Failure, February 2009, Wiley

    Professor john j mcmurray, Professor John GF Cleland

  462. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on β-blockers in SURVIVE†

    Article • European Journal of Heart Failure, February 2009, Wiley

    Professor John GF Cleland

  463. Telemonitoring for heart failure: the only feasible option for good universal care?

    Article • European Journal of Heart Failure, February 2009, Wiley

    Professor John GF Cleland

  464. Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials

    Article • European Journal of Heart Failure, February 2009, Wiley

    Professor John GF Cleland

  465. Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus

    Article • Heart, February 2009, BMJ

    Professor John GF Cleland

  466. Smoking cessation in heart failure: easier said than done

    Article • European Heart Journal, February 2009, European Society of Cardiology

    Professor John GF Cleland

  467. Cardiac Resynchronization Therapy

    Article • Journal of the American College of Cardiology, February 2009, Elsevier

    Professor John GF Cleland

  468. Clinical trials update from the Heart Failure Society of America and the American Heart Association meetings in 2008: SADHART-CHF, COMPARE, MOMENTUM, thyroid hormone analogue study, HF-ACTION, I-PRESERVE, β-interferon study, BACH, and ATHENA

    Article • European Journal of Heart Failure, January 2009, Wiley

    Professor John GF Cleland

  469. The prognostic value of individual NT-proBNP values in chronic heart failure does not change with advancing age

    Article • Heart, January 2009, BMJ

    Professor John GF Cleland

  470. Prevalence and inter-relationship of different Doppler measures of dyssynchrony in patients with heart failure and prolonged QRS: a report from CARE-HF

    Article • Cardiovascular Ultrasound, January 2009, Springer Science + Business Media

    Professor John GF Cleland

  471. The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial

    Article • European Heart Journal, December 2008, European Society of Cardiology

    Professor John GF Cleland

  472. Clinical trials update from European Society of Cardiology meeting 2008: TIME-CHF, BACH, BEAUTIFUL, GISSI-HF, and HOME-HF

    Article • European Journal of Heart Failure, November 2008, Wiley

    Professor John GF Cleland

  473. Oral levosimendan in patients with severe chronic heart failure-The PERSIST study

    Article • European Journal of Heart Failure, November 2008, Wiley

    Professor John GF Cleland

  474. Successful treatment of heart failure with devices requires collaboration

    Article • European Journal of Heart Failure, November 2008, Wiley

    Professor John GF Cleland

  475. Time for a proper study of aspirin after a vascular event?

    Article • BMJ, November 2008, BMJ

    Professor John GF Cleland

  476. Cardiac resynchronization therapy: dyssynchrony imaging from a heart failure perspective

    Article • Current Opinion in Cardiology, November 2008, Wolters Kluwer Health

    Professor John GF Cleland

  477. Ruling out heart failure in primary-care: The cost-benefit of pre-screening using NT-proBNP and QRS width

    Article • International Journal of Cardiology, November 2008, Elsevier

    Professor John GF Cleland

  478. Predictors of Mortality From Pump Failure and Sudden Cardiac Death in Patients With Systolic Heart Failure and Left Ventricular Dyssynchrony: Results of the CARE-HF Trial

    Article • Journal of Cardiac Failure, October 2008, Elsevier

    Professor John GF Cleland

  479. Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452

    Article • European Journal of Heart Failure, September 2008, Wiley

    Professor John GF Cleland

  480. Interpretation of Amino-Terminal Pro-Brain Natriuretic Peptide Levels in the HPS and the CORONA Study

    Article • Journal of the American College of Cardiology, September 2008, Elsevier

    Professor John GF Cleland

  481. State of the art: Using natriuretic peptide levels in clinical practice

    Article • European Journal of Heart Failure, September 2008, Wiley

    Professor John GF Cleland

  482. Predicting the Long-Term Effects of Cardiac Resynchronization Therapy on Mortality From Baseline Variables and the Early Response

    Article • Journal of the American College of Cardiology, August 2008, Elsevier

    Professor John GF Cleland

  483. The Epidemiology of Heart Failure

    Article • July 2008, Oxford University Press (OUP)

    Professor John GF Cleland

  484. Structured telephone support or telemonitoring programs for patients with chronic heart failure

    Article • July 2008, Wiley

    Professor John GF Cleland

  485. Design and Rationale of the URGENT Dyspnea Study: An International, Multicenter, Prospective Study

    Article • American Journal of Therapeutics, July 2008, Wolters Kluwer Health

    Professor John GF Cleland

  486. The prevalence and incidence of left bundle branch block in ambulant patients with chronic heart failure

    Article • European Journal of Heart Failure, July 2008, Wiley

    Professor John GF Cleland

  487. New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey

    Article • European Heart Journal, June 2008, European Society of Cardiology

    Professor John GF Cleland

  488. A Comparison of Patient and Physician-Rated New York Heart Association Class in a Community-Based Heart Failure Clinic

    Article • Journal of Cardiac Failure, June 2008, Elsevier

    Professor John GF Cleland

  489. Cardiac resynchronisation therapy upgrade and occurrence of ventricular arrhythmia

    Article • Heart, June 2008, BMJ

    Professor John GF Cleland

  490. Clinical trials update from the American College of Cardiology 2008: Carisma, Trends, meta-analysis of Cox-2 studies, Hat, on-Target, Hyvet, Accomplish, Momentum, Protect, Horizon-hf and Reverse

    Article • European Journal of Heart Failure, June 2008, Wiley

    Professor John GF Cleland

  491. Perception of symptoms is out of proportion to cardiac pathology in patients with "diastolic heart failure"

    Article • Heart, June 2008, BMJ

    Professor John GF Cleland

  492. The prognostic value of cardiopulmonary exercise testing with a peak respiratory exchange ratio of <1.0 in patients with chronic heart failure

    Article • International Journal of Cardiology, June 2008, Elsevier

    Professor John GF Cleland

  493. Enhanced External Counterpulsation in the Treatment of Chronic Refractory Angina: A Long-term Follow-up Outcome from the International Enhanced External Counterpulsation Patient Registry

    Article • Clinical Cardiology, April 2008, Wiley

    Professor John GF Cleland

  494. The effect of pharmacological stress on intraventricular dyssynchrony in left ventricular systolic dysfunction

    Article • European Journal of Heart Failure, April 2008, Wiley

    Professor John GF Cleland

  495. The timing of development and subsequent clinical course of heart failure after a myocardial infarction

    Article • European Heart Journal, March 2008, European Society of Cardiology

    Professor John GF Cleland

  496. Long-term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: a report from the CARE-HF study

    Article • Heart, March 2008, BMJ

    Professor John GF Cleland

  497. Patients with heart failure who require an implantable defibrillator should have cardiac resynchronisation routinely

    Article • Heart, February 2008, BMJ

    Professor John GF Cleland

  498. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach

    Article • European Heart Journal, February 2008, European Society of Cardiology

    Professor John GF Cleland

  499. Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition

    Article • European Heart Journal, February 2008, European Society of Cardiology

    Professor John GF Cleland

  500. Relationship of high sensitivity C reactive peptide (hsCRP) to prognosis and other prognostic markers in outpatients with heart failure

    Article • American Heart Journal, February 2008, Elsevier

    Professor John GF Cleland

  501. NHS heart failure survey: a survey of acute heart failure admissions in England, Wales and Northern Ireland

    Article • Heart, February 2008, BMJ

    Professor John GF Cleland

  502. Classification of the Level of Evidence in International Guidelines for Acute and Chronic Heart Failure

    Article • January 2008, Springer Science + Business Media

    Professor John GF Cleland

  503. Clinical trials update from the American Heart Association 2007: CORONA, RethinQ, MASCOT, AF-CHF, HART, MASTER, POISE and stem cell therapy

    Article • European Journal of Heart Failure, January 2008, Wiley

    Professor John GF Cleland

  504. Combining the ventilatory response to exercise and peak oxygen consumption is no better than peak oxygen consumption alone in predicting mortality in chronic heart failure

    Article • European Journal of Heart Failure, January 2008, Wiley

    Professor John GF Cleland

  505. Is the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) the Answer to the Cholesterol Paradox in Heart Failure?

    Article • Congestive Heart Failure, January 2008, Wiley

    Professor John GF Cleland

  506. Screening for left ventricular systolic dysfunction in high-risk patients in primary-care: A cost-benefit analysis

    Article • European Journal of Heart Failure, December 2007, Wiley

    Professor John GF Cleland

  507. Rosuvastatin in Older Patients with Systolic Heart Failure

    Article • New England Journal of Medicine, November 2007, New England Journal of Medicine (NEJM/MMS)

    Professor john j mcmurray, Professor John GF Cleland

  508. Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure

    Article • JAMA, November 2007, American Medical Association (AMA)

    Professor john j mcmurray, Professor John GF Cleland

  509. Effect of carvedilol and metoprolol on the mode of death in patients with heart failure

    Article • European Journal of Heart Failure, November 2007, Wiley

    Professor John GF Cleland

  510. Recall of lifestyle advice in patients recently hospitalised with heart failure: A EuroHeart Failure Survey analysis

    Article • European Journal of Heart Failure, November 2007, Wiley

    Professor John GF Cleland

  511. Role of angiotensin receptor blockers in the prevention and management of ischaemic stroke

    Article • European Journal of Neurology, November 2007, Wiley

    Professor John GF Cleland

  512. The Cholesterol Paradox in Heart Failure

    Article • Congestive Heart Failure, November 2007, Wiley

    Professor John GF Cleland

  513. Clinical trials update from the European Society of Cardiology Congress 2007: 3CPO, ALOFT, PROSPECT and statins for heart failure

    Article • European Journal of Heart Failure, October 2007, Wiley

    Professor John GF Cleland

  514. Novel cardiac myosin activators for acute heart failure

    Article • Expert Opinion on Investigational Drugs, October 2007, Informa Healthcare

    Professor John GF Cleland

  515. Worsening Renal Function and Prognosis in Heart Failure: Systematic Review and Meta-Analysis

    Article • Journal of Cardiac Failure, October 2007, Elsevier

    Professor John GF Cleland

  516. Thiazolidinediones, deadly sins, surrogates, and elephants

    Article • The Lancet, September 2007, Elsevier

    Professor John GF Cleland

  517. Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET

    Article • European Journal of Heart Failure, August 2007, Wiley

    Professor John GF Cleland

  518. Prognosis in Heart Failure with a Normal Ejection Fraction

    Article • New England Journal of Medicine, August 2007, New England Journal of Medicine (NEJM/MMS)

    Professor John GF Cleland

  519. Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association

    Article • European Heart Journal, August 2007, European Society of Cardiology

    Professor John GF Cleland

  520. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia

    Article • European Heart Journal, August 2007, European Society of Cardiology

    Professor John GF Cleland

  521. Cardiorespiratory Requirements of the 6-Min Walk Test in Older Patients with Left Ventricular Systolic Dysfunction and No Major Structural Heart Disease

    Article • International Journal of Sports Medicine, August 2007, Thieme Publishing Group

    Professor John GF Cleland

  522. Clinical trials update from Heart Rhythm 2007 and Heart Failure 2007: CARISMA, PREPARE, DAVID II, SAVE-PACE, PROTECT and AREA-IN-CHF

    Article • European Journal of Heart Failure, August 2007, Wiley

    Professor John GF Cleland

  523. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)

    Article • Heart, August 2007, BMJ

    Professor John GF Cleland

  524. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a β-blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial

    Article • European Journal of Heart Failure, August 2007, Wiley

    Professor John GF Cleland

  525. Prediction of Mode of Death in Heart Failure

    Article • Circulation, July 2007, Wolters Kluwer Health

    Professor John GF Cleland

  526. Epidemiology, Associated Factors, and Prognostic Outcomes of Renal Artery Stenosis in Chronic Heart Failure Assessed by Magnetic Resonance Angiography

    Article • The American Journal of Cardiology, July 2007, Elsevier

    Professor John GF Cleland

  527. Should Patients who have Persistent Severe Symptoms Receive a Left Ventricular Assist Device or Cardiac Resynchronization Therapy as the Next Step?

    Article • Heart Failure Clinics, July 2007, Elsevier

    Professor John GF Cleland

  528. Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure

    Article • American Heart Journal, June 2007, Elsevier

    Professor John GF Cleland

  529. Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I

    Article • European Heart Journal, June 2007, European Society of Cardiology

    Professor John GF Cleland

  530. Prognostic value of the VE/VCO2 slope calculated from different time intervals in patients with suspected heart failure

    Article • International Journal of Cardiology, June 2007, Elsevier

    Professor John GF Cleland

  531. The Safety of Amiodarone in Patients With Heart Failure

    Article • Journal of Cardiac Failure, June 2007, Elsevier

    Professor John GF Cleland

  532. Predictors and treatment response with cardiac resynchronization therapy in patients with heart failure characterized by dyssynchrony: a pre-defined analysis from the CARE-HF trial

    Article • European Heart Journal, May 2007, European Society of Cardiology

    Professor John GF Cleland

  533. Implantation of cardiac resynchronization therapy systems in the CARE-HF trial: procedural success rate and safety

    Article • EP Europace, May 2007, European Society of Cardiology

    Professor John GF Cleland

  534. Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet

    Article • European Journal of Heart Failure, May 2007, Wiley

    Professor John GF Cleland

  535. Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: A report from the SPORTIF III and V trials

    Article • European Journal of Heart Failure, May 2007, Wiley

    Professor John GF Cleland

  536. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony

    Article • European Heart Journal, May 2007, European Society of Cardiology

    Professor John GF Cleland

  537. Prevalence of ECG abnormalities in an international survey of patients with suspected or confirmed heart failure at death or discharge

    Article • European Journal of Heart Failure, April 2007, Wiley

    Professor John GF Cleland

  538. Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis

    Article • BMJ, April 2007, BMJ

    Professor John GF Cleland

  539. Fighting against sudden death: A single or multidisciplinary approach

    Article • Journal of Interventional Cardiac Electrophysiology, April 2007, Springer Science + Business Media

    Professor John GF Cleland

  540. The effects of initiation or continuation of statin therapy on cholesterol level and all-cause mortality after the diagnosis of left ventricular systolic dysfunction

    Article • American Heart Journal, April 2007, Elsevier

    Professor John GF Cleland

  541. Effects of applying a standardised management algorithm for moderate to severe renal dysfunction in patients with chronic stable heart failure

    Article • European Journal of Heart Failure, March 2007, Wiley

    Professor John GF Cleland

  542. Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure

    Article • Journal of the American College of Cardiology, March 2007, Elsevier

    Professor John GF Cleland

  543. International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: Data from the EuroHeart Failure Survey

    Article • European Journal of Heart Failure, March 2007, Wiley

    Professor John GF Cleland

  544. Nonpharmacologic Measures and Drug Compliance in Patients with Heart Failure: Data from the EuroHeart Failure Survey

    Article • The American Journal of Cardiology, March 2007, Elsevier

    Professor John GF Cleland

  545. Cardiac Resynchronization for Diabetic Heart Failure Patients

    Article • Diabetes Care, February 2007, American Diabetes Association

    Professor John GF Cleland

  546. Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro) BNP

    Article • EP Europace, February 2007, European Society of Cardiology

    Professor John GF Cleland

  547. Cardiac resynchronization therapy or atrio-biventricular pacing—what should it be called?

    Article • Nature Clinical Practice Cardiovascular Medicine, February 2007, Springer Science + Business Media

    Professor John GF Cleland

  548. An evaluation of two self-report screening measures for mood in an out-patient chronic heart failure population

    Article • International Journal of Geriatric Psychiatry, January 2007, Wiley

    Professor John GF Cleland

  549. Clinical trials update from the American Heart Association 2006: OAT, SALT 1 and 2, MAGIC, ABCD, PABA-CHF, IMPROVE-CHF, and percutaneous mitral annuloplasty

    Article • European Journal of Heart Failure, January 2007, Wiley

    Professor John GF Cleland

  550. Practical Applications of Intravenous Diuretic Therapy in Decompensated Heart Failure

    Article • The American Journal of Medicine, December 2006, Elsevier

    Professor John GF Cleland

  551. Prognostic value of the 6 min walk test and self-perceived symptom severity in older patients with chronic heart failure

    Article • European Heart Journal, November 2006, European Society of Cardiology

    Professor John GF Cleland

  552. The assessment of autonomic function in chronic atrial fibrillation: description of a non-invasive technique based on circadian rhythm of atrioventricular nodal functional refractory periods

    Article • EP Europace, November 2006, European Society of Cardiology

    Professor John GF Cleland

  553. Clinical trials update from the Heart Failure Society of America meeting: FIX-CHF-4, selective cardiac myosin activator and OPT-CHF

    Article • European Journal of Heart Failure, October 2006, Wiley

    Professor John GF Cleland

  554. The effect of altering heart rate on ventricular function in patients with heart failure treated with β-blockers

    Article • American Heart Journal, October 2006, Elsevier

    Professor John GF Cleland

  555. The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation

    Article • European Heart Journal, October 2006, European Society of Cardiology

    Professor John GF Cleland

  556. The perindopril in elderly people with chronic heart failure (PEP-CHF) study

    Article • European Heart Journal, October 2006, European Society of Cardiology

    Professor John GF Cleland

  557. Baseline echocardiographic characteristics of heart failure patients enrolled in a large European multicentre trial (CArdiac REsynchronisation Heart Failure study)

    Article • European Journal of Echocardiography, October 2006, European Society of Cardiology

    Professor John GF Cleland

  558. New generation 3-dimensional echocardiography for left ventricular volumetric and functional measurements: Comparison with cardiac magnetic resonance

    Article • European Journal of Echocardiography, October 2006, European Society of Cardiology

    Professor John GF Cleland

  559. Clinical trials update from the joint European Society and World Congress of Cardiology meeting: PEP-CHF, ACCLAIM and the HHH study

    Article • European Journal of Heart Failure, October 2006, Wiley

    Professor John GF Cleland

  560. Randomized trials are also essential for device therapy: reply

    Article • Journal of Internal Medicine, September 2006, Wiley

    Professor John GF Cleland

  561. The effect of ventricular pacing on measurements of left ventricular function: A comparison between echocardiographic methods and with radionuclide ventriculography☆

    Article • European Journal of Echocardiography, August 2006, European Society of Cardiology

    Professor John GF Cleland

  562. Anemia, Renal Dysfunction, and Their Interaction in Patients With Chronic Heart Failure

    Article • The American Journal of Cardiology, August 2006, Elsevier

    Professor John GF Cleland

  563. Cardiac resynchronization therapy: redefining the role of device therapy in heart failure

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, August 2006, Taylor & Francis

    Professor John GF Cleland

  564. Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC-HF and KW-3902

    Article • European Journal of Heart Failure, August 2006, Wiley

    Professor John GF Cleland

  565. Reply

    Article • Journal of the American College of Cardiology, August 2006, Elsevier

    Professor John GF Cleland

  566. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]

    Article • European Heart Journal, July 2006, European Society of Cardiology

    Professor John GF Cleland

  567. Effect of Cardiac Resynchronization on the Incidence of Atrial Fibrillation in Patients With Severe Heart Failure

    Article • Circulation, July 2006, Wolters Kluwer Health

    Professor John GF Cleland

  568. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator

    Article • European Heart Journal, June 2006, European Society of Cardiology

    Professor John GF Cleland

  569. Adherence and perception of medication in patients with chronic heart failure during a five-year randomised trial

    Article • Patient Education and Counseling, June 2006, Elsevier

    Professor John GF Cleland

  570. Cardiac resynchronisation for patients with heart failure due to left ventricular systolic dysfunction - a systematic review and meta-analysis

    Article • European Journal of Heart Failure, June 2006, Wiley

    Professor John GF Cleland

  571. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET

    Article • European Heart Journal, May 2006, European Society of Cardiology

    Professor John GF Cleland

  572. Excessive breathlessness in patients with diastolic heart failure

    Article • Heart, May 2006, BMJ

    Professor John GF Cleland

  573. Chronic aspirin therapy for the prevention of cardiovascular events: a waste of time, or worse?

    Article • Nature Clinical Practice Cardiovascular Medicine, May 2006, Springer Science + Business Media

    Professor John GF Cleland

  574. Clinical determinants of poor six-minute walk test performance in patients with left ventricular systolic dysfunction and no major structural heart disease

    Article • European Journal of Heart Failure, May 2006, Wiley

    Professor John GF Cleland

  575. Clinical trials update from the American College of Cardiology: Darbepoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND

    Article • European Journal of Heart Failure, May 2006, Wiley

    Professor John GF Cleland

  576. Diabetes Lowers Six-Minute Walk Test Performance in Heart Failure

    Article • Journal of the American College of Cardiology, May 2006, Elsevier

    Professor John GF Cleland

  577. A Comparison of the Effects of Carvedilol and Metoprolol on Well-Being, Morbidity, and Mortality (the “Patient Journey”) in Patients With Heart Failure

    Article • Journal of the American College of Cardiology, April 2006, Elsevier

    Professor John GF Cleland

  578. Pharmacokinetic and Pharmacodynamic Characteristics of β-Blockers: When Differences May Matter

    Article • Journal of Cardiac Failure, April 2006, Elsevier

    Professor John GF Cleland

  579. Left ventricular morphology, global and longitudinal function in normal older individuals: A cardiac magnetic resonance study

    Article • International Journal of Cardiology, March 2006, Elsevier

    Professor John GF Cleland

  580. The immediate and long-term outcome of enhanced external counterpulsation in treatment of chronic stable refractory angina

    Article • Journal of Internal Medicine, March 2006, Wiley

    Professor John GF Cleland

  581. Predicting peak oxygen uptake from 6-min walk test performance in male patients with left ventricular systolic dysfunction

    Article • European Journal of Heart Failure, February 2006, Wiley

    Professor John GF Cleland

  582. Threats, opportunities, and statins in the modern management of heart failureThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

    Article • European Heart Journal, February 2006, European Society of Cardiology

    Professor John GF Cleland

  583. Relation between severity of left ventricular systolic dysfunction and repolarisation abnormalities on the surface ECG: a report from the Euro heart failure survey

    Article • Heart, February 2006, BMJ

    Professor John GF Cleland

  584. Metabolic remodeling in the aging heart

    Article • Journal of Molecular and Cellular Cardiology, January 2006, Elsevier

    Professor John GF Cleland

  585. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE

    Article • European Journal of Heart Failure, December 2005, Wiley

    Professor John GF Cleland

  586. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis

    Article • European Heart Journal, December 2005, European Society of Cardiology

    Professor John GF Cleland

  587. Chronic heart failure, chronotropic incompetence, and the effects of   blockade

    Article • Heart, December 2005, BMJ

    Professor John GF Cleland

  588. How many patients need cardiac resynchronization therapy?The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

    Article • European Heart Journal, December 2005, European Society of Cardiology

    Professor John GF Cleland

  589. N-terminal brain natriuretic peptide as a screening tool for heart failure in the pacemaker population

    Article • European Heart Journal, November 2005, European Society of Cardiology

    Professor John GF Cleland

  590. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial

    Article • European Heart Journal, November 2005, European Society of Cardiology

    Professor John GF Cleland

  591. Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study

    Article • Heart, October 2005, BMJ

    Professor John GF Cleland

  592. Prognostic value of systolic mitral annular velocity measured with Doppler tissue imaging in patients with chronic heart failure caused by left ventricular systolic dysfunction

    Article • Heart, October 2005, BMJ

    Professor John GF Cleland

  593. Cost effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial: reply

    Article • European Heart Journal, October 2005, European Society of Cardiology

    Professor John GF Cleland

  594. Effect of a community heart failure clinic on uptake of   blockers by patients with obstructive airways disease and heart failure

    Article • Heart, October 2005, BMJ

    Professor John GF Cleland

  595. Atrial fibrillation management: a prospective survey in ESC Member Countries

    Article • European Heart Journal, October 2005, European Society of Cardiology

    Professor Massimo Fioranelli, Professor John GF Cleland

  596. The Task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005)

    Article • European Heart Journal, October 2005, European Society of Cardiology

    Professor John GF Cleland

  597. Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE

    Article • European Journal of Heart Failure, October 2005, Wiley

    Professor John GF Cleland

  598. Metabolic gas kinetics depend upon the level of exercise performed

    Article • European Journal of Heart Failure, October 2005, Wiley

    Professor John GF Cleland

  599. Poor Relationship Between Exercise Capacity and Spirometric Measurements in Patients With More Symptomatic Heart Failure

    Article • Journal of Cardiac Failure, October 2005, Elsevier

    Professor John GF Cleland

  600. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure

    Article • European Heart Journal, September 2005, European Society of Cardiology

    Professor John GF Cleland

  601. ACC/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Chronic Heart Failure

    Article • Circulation, September 2005, Wolters Kluwer Health

    Professor John GF Cleland

  602. Anemia and Chronic Heart Failure

    Article • Circulation, September 2005, Wolters Kluwer Health

    Professor John GF Cleland

  603. ACC/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Chronic Heart Failure

    Article • Journal of the American College of Cardiology, September 2005, Elsevier

    Professor John GF Cleland

  604. Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la insuficiencia cardíaca crónica. Versión resumida (actualización 2005)

    Article • Revista Española de Cardiología, September 2005, Elsevier

    Professor John GF Cleland

  605. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure

    Article • European Heart Journal, August 2005, European Society of Cardiology

    Professor John GF Cleland

  606. Clinical trials update from the American College of Cardiology meeting: CARE-HF and the Remission of Heart Failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER

    Article • European Journal of Heart Failure, August 2005, Wiley

    Professor John GF Cleland

  607. Clinical trials update from the European Society of Cardiology Heart Failure meeting and the American College of Cardiology: Darbepoetin alfa study, ECHOS, and ASCOT-BPLA

    Article • European Journal of Heart Failure, August 2005, Wiley

    Professor John GF Cleland

  608. Do discharge codes underestimate hospitalisation due to heart failure? Validation study of hospital discharge coding for heart failure

    Article • European Journal of Heart Failure, August 2005, Wiley

    Professor John GF Cleland

  609. Exploring symptoms in chronic heart failure

    Article • European Journal of Heart Failure, August 2005, Wiley

    Professor John GF Cleland

  610. Meta-analysis does not show that cardiac resynchronisation reduces all-cause mortality

    Article • International Journal of Cardiology, August 2005, Elsevier

    Professor John GF Cleland

  611. Once-Monthly Administration of Darbepoetin Alfa for the Treatment of Patients with Chronic Heart Failure and Anemia

    Article • Journal of Cardiovascular Pharmacology, August 2005, Wolters Kluwer Health

    Professor John GF Cleland

  612. Prevalence and predictors of anxiety and depression in a sample of chronic heart failure patients with left ventricular systolic dysfunction

    Article • European Journal of Heart Failure, August 2005, Wiley

    Professor John GF Cleland

  613. The diagnosis of heart failure in European primary care: The IMPROVEMENT Programme survey of perception and practice

    Article • European Journal of Heart Failure, August 2005, Wiley

    Professor John GF Cleland

  614. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial

    Article • European Heart Journal, July 2005, European Society of Cardiology

    Professor John GF Cleland

  615. Cardiac-Resynchronization Therapy in Heart Failure

    Article • New England Journal of Medicine, July 2005, New England Journal of Medicine (NEJM/MMS)

    Professor John GF Cleland

  616. Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS)

    Article • American Heart Journal, July 2005, Elsevier

    Professor john j mcmurray, Professor John GF Cleland

  617. Multidisciplinary interventions in heart failure

    Article • Heart, July 2005, BMJ

    Professor John GF Cleland

  618. Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction

    Article • The American Journal of Medicine, July 2005, Elsevier

    Professor John GF Cleland

  619. β-Blockers, Exercise, and Ventilation in Chronic Heart Failure

    Article • Journal of Cardiac Failure, June 2005, Elsevier

    Professor John GF Cleland

  620. Exchange of β-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial)

    Article • European Journal of Heart Failure, May 2005, Wiley

    Professor John GF Cleland

  621. The effects of long-term β-blockade on the ventilatory responses to exercise in chronic heart failure

    Article • European Journal of Heart Failure, May 2005, Wiley

    Professor John GF Cleland

  622. Atherosclerotic renovascular disease in chronic heart failure: should we intervene?

    Article • European Heart Journal, May 2005, European Society of Cardiology

    Professor John GF Cleland

  623. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)

    Article • European Heart Journal, May 2005, European Society of Cardiology

    Professor John GF Cleland

  624. Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction

    Article • Heart, May 2005, BMJ

    Professor John GF Cleland

  625. Hierarchical cardiac MRI segmentation using shaped region-interface descriptors

    Article • International Congress Series, May 2005, Elsevier

    Professor John GF Cleland

  626. Noninvasive Home Telemonitoring for Patients With Heart Failure at High Risk of Recurrent Admission and Death

    Article • Journal of the American College of Cardiology, May 2005, Elsevier

    Professor John GF Cleland

  627. Symptoms in Patients With Heart Failure are Prognostic Predictors: Insights From COMET

    Article • Journal of Cardiac Failure, May 2005, Elsevier

    Professor John GF Cleland

  628. The reproducibility and sensitivity of the 6-min walk test in elderly patients with chronic heart failure

    Article • European Heart Journal, April 2005, European Society of Cardiology

    Professor John GF Cleland

  629. The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure

    Article • New England Journal of Medicine, April 2005, New England Journal of Medicine (NEJM/MMS)

    Professor John GF Cleland

  630. Are There Clinically Important Differences Between Beta-Blockers in Heart Failure?

    Article • Heart Failure Clinics, April 2005, Elsevier

    Professor John GF Cleland

  631. Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review

    Article • European Heart Journal, March 2005, European Society of Cardiology

    Professor John GF Cleland

  632. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET

    Article • European Heart Journal, March 2005, European Society of Cardiology

    Professor John GF Cleland

  633. Longitudinal myocardial dysfunction in healthy older subjects as a manifestation of cardiac ageing

    Article • Age and Ageing, February 2005, Oxford University Press (OUP)

    Professor John GF Cleland

  634. Baseline characteristics of patients recruited into the CARE-HF study

    Article • European Journal of Heart Failure, February 2005, Wiley

    Professor John GF Cleland

  635. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study

    Article • European Journal of Heart Failure, February 2005, Wiley

    Professor John GF Cleland

  636. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET

    Article • American Heart Journal, February 2005, Elsevier

    Professor John GF Cleland

  637. Patients with treatable malignant diseases -- including heart failure -- are entitled to specialist care

    Article • Canadian Medical Association Journal, January 2005, Canadian Medical Association (CMA)

    Professor John GF Cleland

  638. Clinical trials update from the American Heart Association meeting: ACORN-CSD, primary care trial of chronic disease management, PEACE, CREATE, SHIELD, A-HeFT, GEMINI, vitamin E meta-analysis, ESCAPE, CARP, and SCD-HeFT cost-effectiveness study

    Article • European Journal of Heart Failure, January 2005, Wiley

    Professor John GF Cleland

  639. Comparison of selective ETAand ETBreceptor antagonists in patients with chronic heart failure

    Article • European Journal of Heart Failure, January 2005, Wiley

    Professor John GF Cleland

  640. Letter from the outgoing Editor-in-Chief of the European Journal of Heart Failure

    Article • European Journal of Heart Failure, January 2005, Wiley

    Professor John GF Cleland

  641. Clinical trials update from the Heart Failure Society of America: EMOTE, HERB-CHF, BEST genetic sub-study and RHYTHM-ICD

    Article • European Journal of Heart Failure, December 2004, Wiley

    Professor John GF Cleland

  642. Trial finds no evidence that aspirin and warfarin improve outcomes in people with heart failure

    Article • Evidence-based Cardiovascular Medicine, December 2004, Elsevier

    Professor John GF Cleland

  643. The prevalence of abnormal glucose regulation in patients with coronary artery disease across EuropeThe Euro Heart Survey on diabetes and the heart

    Article • European Heart Journal, November 2004, European Society of Cardiology

    Professor John GF Cleland

  644. Can cardiac-resynchronization therapy reduce mortality in patients suffering from advanced chronic heart failure?

    Article • Nature Clinical Practice Cardiovascular Medicine, November 2004, Springer Science + Business Media

    Professor John GF Cleland

  645. Clinical trials update from the European Society of Cardiology: SENIORS, ACES, PROVE-IT, ACTION, and the HF-ACTION trial

    Article • European Journal of Heart Failure, October 2004, Wiley

    Professor John GF Cleland

  646. Diagnosing heart failure in primary care: lessons from EPICA

    Article • European Journal of Heart Failure, October 2004, Wiley

    Professor John GF Cleland

  647. Exercise capacity and cardiac function assessed by tissue Doppler imaging in chronic heart failure

    Article • Heart, October 2004, BMJ

    Professor John GF Cleland

  648. The utility of a comprehensive cardiac magnetic resonance examination for the evaluation of patients with heart failure

    Article • Heart, October 2004, BMJ

    Professor John GF Cleland

  649. Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy

    Article • European Journal of Heart Failure, August 2004, Wiley

    Professor John GF Cleland

  650. Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe

    Article • European Journal of Heart Failure, August 2004, Wiley

    Professor John GF Cleland

  651. The TORCH (TOwards a Revolution in COPD Health) survival study protocol: Fig. 1.—

    Article • European Respiratory Journal, August 2004, European Respiratory Society (ERS)

    Professor John GF Cleland

  652. The Warfarin/Aspirin study in heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure

    Article • American Heart Journal, July 2004, Elsevier

    Professor John GF Cleland

  653. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey

    Article • European Heart Journal, July 2004, European Society of Cardiology

    Professor John GF Cleland

  654. A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design

    Article • Journal of Cardiac Failure, June 2004, Elsevier

    Professor John GF Cleland

  655. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure

    Article • European Journal of Heart Failure, June 2004, Wiley

    Professor John GF Cleland

  656. Diastolic heart failure. Paroxysmal or chronic?

    Article • European Journal of Heart Failure, June 2004, Wiley

    Professor John GF Cleland

  657. Letter to the editor

    Article • European Journal of Heart Failure, June 2004, Wiley

    Professor John GF Cleland

  658. Are hematinic deficiencies the cause of anemia in chronic heart failure?

    Article • American Heart Journal, May 2004, Elsevier

    Professor John GF Cleland

  659. The Warfarin and Antiplatelet Therapy in Heart Failure Trial (WATCH): rationale, design, and baseline patient characteristics

    Article • Journal of Cardiac Failure, April 2004, Elsevier

    Professor John GF Cleland

  660. The reversibility of increased airways resistance in chronic heart failure measured by impulse oscillometry

    Article • Journal of Cardiac Failure, April 2004, Elsevier

    Professor John GF Cleland

  661. A Description of the Clinical Characteristics at Baseline of Patients Recruited into the Carvedilol or Metoprolol European Trial (COMET)

    Article • Cardiovascular Drugs and Therapy, March 2004, Springer Science + Business Media

    Professor John GF Cleland

  662. Controlling persistent atrial fibrillation

    Article • QJM, March 2004, Oxford University Press (OUP)

    Professor John GF Cleland

  663. Natriuretic peptides for heart failure. Fashionable? Useful? Necessary?

    Article • European Journal of Heart Failure, March 2004, Wiley

    Professor John GF Cleland

  664. A method to reduce loss to follow-up in clinical trials: informed, withdrawal of consent

    Article • European Journal of Heart Failure, January 2004, Wiley

    Professor John GF Cleland

  665. Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure

    Article • Evidence-Based Medicine, January 2004, BMJ

    Professor John GF Cleland

  666. Clinical trials update from the American Heart Association meeting: Ω-3 fatty acids and arrhythmia risk in patients with an implantable defibrillator, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT and PA

    Article • European Journal of Heart Failure, January 2004, Wiley

    Professor John GF Cleland

  667. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure

    Article • Expert Review of Cardiovascular Therapy, January 2004, Taylor & Francis

    Professor John GF Cleland

  668. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?

    Article • Journal of the American College of Cardiology, December 2003, Elsevier

    Professor John GF Cleland

  669. Carvedilol reduces mortality compared with metoprolol in chronic heart failure

    Article • Evidence-based Cardiovascular Medicine, December 2003, Elsevier

    Professor John GF Cleland

  670. Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity

    Article • British Journal of Clinical Pharmacology, November 2003, Wiley

    Professor John GF Cleland

  671. The CHARM programme

    Article • The Lancet, November 2003, Elsevier

    Professor john j mcmurray, Professor John GF Cleland

  672. A systematic review of telemonitoring for the management of heart failure

    Article • European Journal of Heart Failure, October 2003, Wiley

    Professor John GF Cleland

  673. Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM

    Article • European Journal of Heart Failure, October 2003, Wiley

    Professor John GF Cleland

  674. Delivering the cumulative benefits of triple therapy to improve outcomes in heart failure

    Article • Journal of the American College of Cardiology, October 2003, Elsevier

    Professor John GF Cleland

  675. Myocardial dysfunction: hibernation and remodelling

    Article • The Lancet, October 2003, Elsevier

    Professor John GF Cleland

  676. Reliability of reporting left ventricular systolic function by echocardiography: A systematic review of 3 methods

    Article • American Heart Journal, September 2003, Elsevier

    Professor John GF Cleland

  677. Cardiac resynchronization halves death from heart failure

    Article • Evidence-based Cardiovascular Medicine, September 2003, Elsevier

    Professor John GF Cleland

  678. Longitudinal ventricular function: normal values of atrioventricular annular and myocardial velocities measured with quantitative two-dimensional color doppler tissue imaging

    Article • Journal of the American Society of Echocardiography, September 2003, Elsevier

    Professor John GF Cleland

  679. Clinical trials update from the European Society of Cardiology Heart Failure meeting: COMET, COMPANION, Tezosentan and SHAPE

    Article • European Journal of Heart Failure, August 2003, Wiley

    Professor John GF Cleland

  680. Pain Management in Patients With Osteoarthritis

    Article • JAMA, July 2003, American Medical Association (AMA)

    Professor John GF Cleland

  681. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial

    Article • The Lancet, July 2003, Elsevier

    Professor John GF Cleland

  682. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial

    Article • The Lancet, July 2003, Elsevier

    Professor John GF Cleland

  683. The prevalence of heart failure and asymptomatic left ventricular systolic dysfunction in a typical regional pacemaker population

    Article • European Heart Journal, June 2003, European Society of Cardiology

    Professor John GF Cleland

  684. The heart failure revascularisation trial (HEART): rationale, design and methodology

    Article • European Journal of Heart Failure, June 2003, Wiley

    Professor John GF Cleland

  685. Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans

    Article • European Journal of Heart Failure, June 2003, Wiley

    Professor John GF Cleland

  686. The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe Part 2: treatment

    Article • European Heart Journal, March 2003, European Society of Cardiology

    Professor John GF Cleland

  687. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis

    Article • European Heart Journal, March 2003, European Society of Cardiology

    Professor John GF Cleland

  688. Levosimendan reduces mortality compared wtih dobutamine in severe low output heart failure

    Article • Evidence-based Cardiovascular Medicine, March 2003, Elsevier

    Professor John GF Cleland

  689. There is little evidence that intravenous inotropes improve outcomes in heart failure

    Article • Evidence-based Cardiovascular Medicine, March 2003, Elsevier

    Professor John GF Cleland

  690. β-Blockers for heart failure: why, which, when, and where

    Article • Medical Clinics of North America, March 2003, Elsevier

    Professor John GF Cleland

  691. A Happy and Prosperous New Year to All Our Readers!

    Article • European Journal of Heart Failure, January 2003, Wiley

    Professor John GF Cleland

  692. Clinical trials update from the American Heart Association meeting: PROSPER, DIAL, home care monitoring trials, immune modulation therapy, COMPANION and anaemia in heart failure

    Article • European Journal of Heart Failure, January 2003, Wiley

    Professor John GF Cleland

  693. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial

    Article • European Journal of Heart Failure, January 2003, Wiley

    Professor John GF Cleland

  694. Color tissue Doppler-derived long-axis left ventricular function in heart failure with preserved global systolic function

    Article • The American Journal of Cardiology, November 2002, Elsevier

    Professor John GF Cleland

  695. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey

    Article • The Lancet, November 2002, Elsevier

    Professor John GF Cleland

  696. Clinical trials update from the European Society of Cardiology: CARMEN, EARTH, OPTIMAAL, ACE, TEN-HMS, MAGIC, SOLVD-X and PATH-CHF II

    Article • European Journal of Heart Failure, October 2002, Wiley

    Professor John GF Cleland

  697. Airway resistance in chronic heart failure measured by impulse oscillometry

    Article • Journal of Cardiac Failure, August 2002, Elsevier

    Professor John GF Cleland

  698. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH

    Article • European Journal of Heart Failure, August 2002, Wiley

    Professor John GF Cleland

  699. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis

    Article • European Journal of Heart Failure, August 2002, Wiley

    Professor John GF Cleland

  700. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial

    Article • The Lancet, July 2002, Elsevier

    Professor John GF Cleland

  701. Clinical trials update: highlights of the scientific sessions of The American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL

    Article • European Journal of Heart Failure, June 2002, Wiley

    Professor John GF Cleland

  702. How to assess new treatments for the management of heart failure: composite scoring systems to assess the patients’ clinical journey

    Article • European Journal of Heart Failure, June 2002, Wiley

    Professor John GF Cleland

  703. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET

    Article • European Journal of Heart Failure, June 2002, Wiley

    Professor John GF Cleland

  704. The European Journal of Heart Failure; update on the story so far!

    Article • European Journal of Heart Failure, June 2002, Wiley

    Professor John GF Cleland

  705. Levosimendan: a new era for inodilator therapy for heart failure?

    Article • Current Opinion in Cardiology, May 2002, Wolters Kluwer Health

    Professor John GF Cleland

  706. Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH

    Article • European Journal of Heart Failure, January 2002, Wiley

    Professor John GF Cleland

  707. Diastolic heart failure: neglected or misdiagnosed?

    Article • Journal of the American College of Cardiology, January 2002, Elsevier

    Professor John GF Cleland

  708. Is aspirin ″the weakest link” in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease

    Article • Progress in Cardiovascular Diseases, January 2002, Elsevier

    Professor John GF Cleland

  709. No reduction in cardiovascular risk with NSAIDs—including aspirin?

    Article • The Lancet, January 2002, Elsevier

    Professor John GF Cleland

  710. Article • Heart Failure Reviews, January 2002, Springer Science + Business Media

    Professor John GF Cleland

  711. Article • Heart Failure Reviews, January 2002, Springer Science + Business Media

    Professor John GF Cleland

  712. ACE Inhibitors for ‘Diastolic’ Heart Failure? Reasons not to jump to premature conclusions about the efficacy of ACE inhibitors among older patients with heart failure

    Article • European Journal of Heart Failure, December 2001, Wiley

    Professor John GF Cleland

  713. Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology - WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME

    Article • European Journal of Heart Failure, December 2001, Wiley

    Professor John GF Cleland

  714. Validation of an echocardiographic wall motion index in heart failure due to ischaemic heart disease

    Article • European Journal of Heart Failure, December 2001, Wiley

    Professor John GF Cleland

  715. Endothelin antagonists for chronic heart failure: do they have a role?

    Article • European Heart Journal, October 2001, European Society of Cardiology

    Professor John GF Cleland

  716. What is the optimal medical management of ischaemic heart failure?

    Article • British Medical Bulletin, October 2001, Oxford University Press (OUP)

    Professor John GF Cleland

  717. Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study

    Article • European Heart Journal, September 2001, European Society of Cardiology

    Professor John GF Cleland

  718. Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart failure?

    Article • Current Opinion in Nephrology & Hypertension, September 2001, Wolters Kluwer Health

    Professor John GF Cleland

  719. Clinical trials update: Highlights of the Scientific Sessions of Heart Failure 2001, a meeting of the Working Group on Heart Failure of the European Society of Cardiology. CONTAK-CD, CHRISTMAS, OPTIME-CHF

    Article • European Journal of Heart Failure, August 2001, Wiley

    Professor John GF Cleland

  720. The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points

    Article • European Journal of Heart Failure, August 2001, Wiley

    Professor John GF Cleland

  721. Chronic heart failure and micronutrients

    Article • Journal of the American College of Cardiology, June 2001, Elsevier

    Professor John GF Cleland

  722. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001

    Article • European Journal of Heart Failure, June 2001, Wiley

    Professor John GF Cleland

  723. The heart failure epidemic: exactly how big is it?

    Article • European Heart Journal, April 2001, European Society of Cardiology

    Professor John GF Cleland

  724. How do you measure exercise capacity in chronic heart failure?

    Article • European Heart Journal, April 2001, European Society of Cardiology

    Professor John GF Cleland

  725. What is the optimal medical management of ischemic heart failure?

    Article • Progress in Cardiovascular Diseases, March 2001, Elsevier

    Professor John GF Cleland

  726. Clinical events leading to the progression of heart failure: insights from a national database of hospital discharges

    Article • European Heart Journal, January 2001, European Society of Cardiology

    Professor John GF Cleland

  727. Recommendations for exercise testing in chronic heart faliure patients

    Article • European Heart Journal, January 2001, European Society of Cardiology

    Professor John GF Cleland

  728. Clinical trials update: highlights of the scientific sessions of the American Heart Association year 2000: Val HeFT, COPERNICUS, MERIT, CIBIS-II, BEST, AMIOVIRT, V-MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myobl

    Article • European Journal of Heart Failure, January 2001, Wiley

    Professor John GF Cleland

  729. Clinical trials update: IMPROVEMENT-HF, COPERNICUS, MUSTIC, ASPECT-II, APRICOT and HEART

    Article • European Journal of Heart Failure, December 2000, Wiley

    Professor John GF Cleland

  730. Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study

    Article • European Journal of Heart Failure, December 2000, Wiley

    Professor John GF Cleland

  731. Is the prognosis of heart failure improving?

    Article • Journal of the American College of Cardiology, December 2000, Elsevier

    Professor John GF Cleland

  732. Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials

    Article • European Journal of Heart Failure, September 2000, Wiley

    Professor John GF Cleland

  733. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance. Are they interchangeable?

    Article • European Heart Journal, August 2000, European Society of Cardiology

    Professor John GF Cleland

  734. Pulmonary artery pressure measurement during exercise testing in patients with suspected pulmonary hypertension

    Article • European Respiratory Journal, August 2000, European Respiratory Society (ERS)

    Professor John GF Cleland

  735. Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT

    Article • European Journal of Heart Failure, June 2000, Wiley

    Professor John GF Cleland

  736. Systematic review of the management of atrial fibrillation in patients with heart failure

    Article • European Heart Journal, April 2000, European Society of Cardiology

    Professor John GF Cleland

  737. Implantable left ventricular assist systems (LVAS): Recent results. A report from a series of meetings sponsored by the Study Group on Advanced Heart Failure of the Working Group on Heart Failure

    Article • European Journal of Heart Failure, March 2000, Wiley

    Professor John GF Cleland

  738. Implantable left ventricular assist systems: clinical trials

    Article • European Journal of Heart Failure, March 2000, Wiley

    Professor John GF Cleland

  739. Update of ELITE-II, BEST, CHAMP, and IMPRESS clinical trials in heart failure

    Article • European Journal of Heart Failure, March 2000, Wiley

    Professor John GF Cleland

  740. The Carvedilol Hibernation Reversible Ischaemia Trial, Marker of Success (CHRISTMAS) study

    Article • International Journal of Cardiology, February 2000, Elsevier

    Professor John GF Cleland

  741. Review: long-term beta-blocker use reduces mortality after myocardial infarction

    Article • Evidence-Based Medicine, January 2000, BMJ

    Professor John GF Cleland

  742. Article • Heart Failure Reviews, January 2000, Springer Science + Business Media

    Professor John GF Cleland

  743. Disruption of the relationship between renin and atrial natriuretic peptide early in the course of ventricular dysfunction

    Article • European Journal of Heart Failure, December 1999, Wiley

    Professor John GF Cleland

  744. The LIDO, HOPE, MOXCON and WASH studies

    Article • European Journal of Heart Failure, December 1999, Wiley

    Professor John GF Cleland

  745. Depression and heart failure — not yet a target for therapy?

    Article • European Heart Journal, November 1999, European Society of Cardiology

    Professor John GF Cleland

  746. Survival trends, coronary event rates, and the MONICA project

    Article • The Lancet, September 1999, Elsevier

    Professor John GF Cleland

  747. Heart failure update

    Article • European Journal of Heart Failure, August 1999, Wiley

    Professor John GF Cleland

  748. Is the prognosis of heart failure improving?

    Article • European Journal of Heart Failure, August 1999, Wiley

    Professor John GF Cleland

  749. Perindopril for elderly people with chronic heart failure: the PEP-CHF study

    Article • European Journal of Heart Failure, August 1999, Wiley

    Professor John GF Cleland

  750. Heart Failure - taking the lead

    Article • European Journal of Heart Failure, June 1999, Wiley

    Professor John GF Cleland

  751. Heart Failure due to Ischaemic Heart Disease: Epidemiology, Pathophysiology and Progression

    Article • Journal of Cardiovascular Pharmacology, June 1999, Wolters Kluwer Health

    Professor John GF Cleland

  752. Increasing awareness and improving the management of heart failure in Europe: the IMPROVEMENT of HF initiative

    Article • European Journal of Heart Failure, June 1999, Wiley

    Professor John GF Cleland

  753. The Carvedilol Hibernation Reversible Ischaemia Trial; Marker of Success (CHRISTMAS)

    Article • European Journal of Heart Failure, June 1999, Wiley

    Professor John GF Cleland

  754. Update of REACH-1 and MERIT-HF clinical trials in heart failure

    Article • European Journal of Heart Failure, June 1999, Wiley

    Professor John GF Cleland

  755. EndothelinBreceptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction

    Article • Journal of the American College of Cardiology, March 1999, Elsevier

    Professor john j mcmurray, Professor John GF Cleland

  756. Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study

    Article • European Journal of Heart Failure, March 1999, Wiley

    Professor John GF Cleland

  757. The WASH study (Warfarin/Aspirin Study in Heart failure) rationale, design and end-points

    Article • European Journal of Heart Failure, March 1999, Wiley

    Professor John GF Cleland

  758. Update of recent clinical trials in heart failure and myocardial infarction

    Article • European Journal of Heart Failure, March 1999, Wiley

    Professor John GF Cleland

  759. Editor's note

    Article • European Journal of Heart Failure, March 1999, Wiley

    Professor John GF Cleland

  760. Sudden death in heart failure: vascular or electrical?

    Article • European Journal of Heart Failure, March 1999, Wiley

    Professor John GF Cleland

  761. Article • Heart Failure Reviews, January 1999, Springer Science + Business Media

    Professor John GF Cleland

  762. Article • Heart Failure Reviews, January 1999, Springer Science + Business Media

    Professor John GF Cleland

  763. Etiology and response to drug treatment in heart failure

    Article • Journal of the American College of Cardiology, November 1998, Elsevier

    Professor John GF Cleland

  764. Endothelin-1 has haemodynamic effects at pathophysiological concentrations in patients with left ventricular dysfunction

    Article • Cardiovascular Research, September 1998, European Society of Cardiology

    Professor john j mcmurray, Professor John GF Cleland

  765. Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995

    Article • European Heart Journal, July 1998, European Society of Cardiology

    Professor John GF Cleland

  766. Risk stratification in chronic heart failure

    Article • European Heart Journal, May 1998, European Society of Cardiology

    Professor John GF Cleland

  767. Regional differences in the characteristics and treatment of patients participating in an international heart failure trial

    Article • Journal of Cardiac Failure, March 1998, Elsevier

    Professor John GF Cleland

  768. Economic implications of the Total Ischaemic Burden Bisoprolol Study (TIBBS) follow-up

    Article • Journal of Medical Economics, January 1998, Informa Healthcare

    Professor John GF Cleland

  769. β-Blockers for Chronic Heart Failure: From Prejudice to Enlightenment

    Article • Journal of Cardiovascular Pharmacology, January 1998, Wolters Kluwer Health

    Professor John GF Cleland

  770. Article • Cardiovascular Drugs and Therapy, January 1997, Springer Science + Business Media

    Professor John GF Cleland

  771. Effects of aging on neuroendocrine activation in subjects and patients in the presence and absence of heart failure with left ventricular systolic dysfunction

    Article • The American Journal of Cardiology, June 1996, Elsevier

    Professor John GF Cleland

  772. Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic clinical research

    Article • Current Opinion in Cardiology, May 1996, Wolters Kluwer Health

    Professor John GF Cleland

  773. Shortened duration of post-ischemic hyperemic blood flow in the forearm of patients with heart failure

    Article • The American Journal of Cardiology, February 1996, Elsevier

    Professor John GF Cleland

  774. Clinical Trials Report: Cardiovascular & Renal: Ongoing and planned clinical trials in chronic heart failure and left ventricular dysfunction

    Article • Expert Opinion on Investigational Drugs, November 1995, Informa Healthcare

    Professor john j mcmurray, Professor John GF Cleland

  775. The standard electrocardiogram as a screening test for hypertrophic cardiomyopathy

    Article • The American Journal of Cardiology, October 1995, Elsevier

    Professor John GF Cleland

  776. Is aspirin safe for patients with heart failure?

    Article • Heart, September 1995, BMJ

    Professor John GF Cleland

  777. Angiography and the aetiology of heart failure.

    Article • Postgraduate Medical Journal, August 1995, BMJ

    Professor John GF Cleland

  778. Renal response to candoxatrilat in patients with heart failure

    Article • Journal of the American College of Cardiology, May 1995, Elsevier

    Professor John GF Cleland

  779. ACE inhibitors in heart failure. What dose?

    Article • Postgraduate Medical Journal, February 1995, BMJ

    Professor John GF Cleland

  780. Short-term effects of right atrial, right ventricular apical, and atrioventricular sequential pacing on myocardial oxygen consumption and cardiac efficiency in patients with coronary artery disease

    Article • Heart, October 1994, BMJ

    Professor John GF Cleland

  781. ACE inhibitors for heart failure: a question of dose

    Article • Heart, September 1994, BMJ

    Professor John GF Cleland

  782. ACE inhibitors: current understanding and future directions

    Article • Heart, September 1994, BMJ

    Professor John GF Cleland

  783. How do ACE inhibitors reduce mortality in patients with left ventricular dysfunction with and without heart failure: remodelling, resetting, or sudden death?

    Article • Heart, September 1994, BMJ

    Professor John GF Cleland

  784. Enhanced basal nitric oxide production in heart failure: another failed counter-regulatory vasodilator mechanism?

    Article • The Lancet, August 1994, Elsevier

    Professor John GF Cleland

  785. Optimising heart failure pharmacotherapy: the ideal combination

    Article • Heart, August 1994, BMJ

    Professor John GF Cleland

  786. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure

    Article • American Heart Journal, March 1994, Elsevier

    Professor Edward G D Tuddenham, Professor John GF Cleland

  787. Sarcoid, amyloid and heart failure

    Article • International Journal of Cardiology, September 1993, Elsevier

    Professor John GF Cleland

  788. Bronchial Hyperresponsiveness in Heart Failure

    Article • New England Journal of Medicine, May 1993, New England Journal of Medicine (NEJM/MMS)

    Professor John GF Cleland

  789. Cardioreparation and the Concept of Modulating Cardiovascular Structure and Function

    Article • Blood Pressure, January 1993, Taylor & Francis

    Professor John GF Cleland

  790. Modification of atherosclerosis by agents that do not lower cholesterol

    Article • Heart, January 1993, BMJ

    Professor John GF Cleland

  791. A comparison of the effects of the selective peripheralα 1-blocker terazosin with the selectiveβ 1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension

    Article • Clinical Autonomic Research, December 1992, Springer Science + Business Media

    Professor John GF Cleland

  792. Angiotensin-converting enzyme inhibitors, left ventricular dysfunction, and early heart failure

    Article • The American Journal of Cardiology, October 1992, Elsevier

    Professor John GF Cleland

  793. Impaired Left Lower Lobe Ventilation in Patients with Cardiomegaly

    Article • CHEST Journal, May 1992, Elsevier

    Professor John GF Cleland

  794. Angiotensin converting enzyme inhibitors for hypertension and heart failure?

    Article • Postgraduate Medical Journal, January 1992, BMJ

    Professor John GF Cleland

  795. Arrhythmias, catecholamines and electrolytes

    Article • The American Journal of Cardiology, January 1988, Elsevier

    Professor John GF Cleland

  796. Total body electrolyte composition in patients with heart failure: a comparison with normal subjects and patients with untreated hypertension.

    Article • Heart, September 1987, BMJ

    Professor John GF Cleland

  797. The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure

    Article • American Heart Journal, July 1986, Elsevier

    Professor John GF Cleland

  798. Combination of verapamil and beta blockers in systemic hypertension

    Article • The American Journal of Cardiology, February 1986, Elsevier

    Professor John GF Cleland

  799. The effects of prostacyclin (PGI2) on haematological and haemodynamic parameters, and lung histology in puppies undergoing cardiopulmonary bypass surgery with profound hypothermia

    Article • Prostaglandins Leukotrienes and Medicine, January 1985, Elsevier

    Professor John GF Cleland

  800. Angiotensin II levels, hemodynamics, and sympathoadrenal function after low-dose captopril in heart failure

    Article • The American Journal of Medicine, November 1984, Elsevier

    Professor John GF Cleland